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ABSTRACT 
Dihydrodipicolinate synthase (DHDPS) is an enzyme which catalyzes the first step of the 
lysine biosynthesis pathway in bacteria and plants. Deletion of the gene encoding DHDPS results 
in non-viable bacteria, therefore DHDPS is considered a validated drug target. The enzyme is 
feedback-regulated by lysine, and structural studies have shown that the tetrameric enzyme 
contains two allosteric sites, each of which bind two lysine molecules. The Palmer laboratory has 
previously developed a potent inhibitor "bislysine" that mimics the structure of two bound lysine 
molecules. Previous work showed that S-aminoethylcysteine ("thialysine") was a much poorer 
inhibitor than lysine, despite the structural similarity of the two compounds. This thesis describes 
the synthesis of new allosteric inhibitors of DHDPS, with the goal of defining their structural and 
chemical properties, such as inhibitor side chain length and pKa, that lead to inhibition.  
Racemic analogs of lysine were generated using the amidomalonic ester synthesis. Analogs 
of bislysine were generated from dimethyl 2,5-bis([(tertbutoxy)carbonyl]amino) hexanedioate by 
treatment with lithium diisopropylamide followed by alkylation using various electrophiles. This 
alkylation step hampers the overall process because it proceeds in low yield (typically near 10%). 
Studies were undertaken in an attempt to understand the factors influencing this reaction; however, 
variations in the reaction times, solvent composition, and additives did not improve the yield 
appreciably.  
All the inhibitors were tested using the established DHDPS-DHDPR coupled assay to 
estimate the IC50 values. The lysine analogue (±)-(E)-2,6-diaminohex-4-enoic acid, which has a 
double bond in the side chain as the only modification, showed weaker inhibition (IC50
 = 3.7  mM) 
compared to racemic lysine (IC50 = 0.2 mM). The altered pKa of the ε-amino group, which makes 
a hydrogen bond with His59 when bound to the allosteric site, is proposed to account for the loss 
of activity. Triazolylmethylglycine, which is predicted to have a pKa value closer to lysine, but 
contains a shorter side chain, was an even weaker inhibitor. Bis-amino acid versions of these 
compounds were much stronger inhibitors. A bis-analog of para-aminobenzylglycine showed 
weak inhibition as well, suggesting this bulkier compound, with a much lower side chain pKa, 
could still bind to the allosteric cavity.  
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1 INTRODUCTION 
1.1 Need for new antibacterial agents 
Antibiotic resistance in bacteria is a rapidly growing problem in the treatment of infectious 
diseases.1 Since the introduction of penicillin in the 1940s to cure infections, several other 
antibiotics were discovered and were used extensively to cure previously untreatable pathogenic 
diseases.2 However, such rampant use of antibiotics over a prolonged period led to the evolution 
of resistant strains of bacteria. Such bacteria have resulted in a relapse of infections which are now 
more difficult to control. The emergence of resistance in bacteria has reached an alarming level 
today rendering many antibiotics ineffective. According to a report by WHO in 2014, a survey 
conducted on the most common infection-causing bacteria such as Escherichia coli, Klebsiella 
pneumoniae, Neisseria gonorrhoeae, Staphylococcus aureus, Mycobacterium tuberculosis and 
Shigella species showed that they are rapidly showing resistance to the antibiotics which were 
previously used successfully to treat these infections.3 Evolution of resistance mechanisms in 
bacteria is a continuous process, which means that the effectiveness of every new drug developed 
will decrease over time. Even though there are many synthetic and natural antibiotics in clinical 
trial at present, it’s only a matter of time before they will be ineffective due to bacterial resistance. 
Hence, there will always be a need to find new antibacterial agents and drug targets, and to have a 
good understanding of the mechanism involved in drug resistance and drug action.2,4  
Antibiotics act by inhibiting various cellular processes, for example cell division and DNA 
replication, RNA and nucleotide synthesis, protein synthesis and cell wall biosynthesis, which are 
vital to the survival of the pathogen.5 This dissertation describes the synthesis and study of 
inhibitors of dihydrodipicolinate synthase (DHDPS), an enzyme in the lysine biosynthesis pathway 
of most bacteria that has been validated as a drug target.6 
1.2 Peptidoglycan assembly in bacteria 
A Gram-negative bacterial cell wall consists of a cell membrane, a peptidoglycan layer and 
an outer membrane. Peptidoglycan is a complex structure formed by polysaccharide chains which 
2 
 
are cross-linked by pentapeptide chains.7 The process of peptidoglycan construction is shown 
schematically in Figure 1.1.  
 
Figure 1.1. Peptidoglycan synthesis and prevalent antibiotics (red), targeting various 
enzymatic steps. Figure adapted from C. Walsh.8 
The polysaccharide is made up of alternating units of N-acetylmuramic acid (MurNAc) and N-
acetyl glucosamine (GlcNAc). The peptidoglycan assembly starts in the cytoplasm with the 
conversion of uridyl diphosphate-linked GlcNAc (UDP-GlcNAc) to UDP-MurNAc, both of which 
are the components of peptidoglycan (PG) monomer.9 A peptide chain is then attached to UDP-
MurNAc in a stepwise manner following the sequence L-Ala-D-Glu-m-DAP-D-Ala-D-Ala for 
Gram-negative bacteria (Figure 1.2). In Gram-positive bacteria, m-DAP (meso-diaminopimelate) 
is replaced by a lysine residue.10 The resulting muramyl dipeptide is then anchored to the cell 
membrane via a C55 undecaprenyl phosphate, which is a carrier lipid and performs the function 
of transporting the muramyl peptide across the hydrophobic membrane.11  The last cytoplasmic 
step is the attachment of a GlcNAc unit to the muramyl pentapeptide to complete the PG monomer. 
The monomer is then transferred to the periplasm via the C55 transporter where it is assimilated 
into the nascent peptidoglycan by transglycosylation and transpeptidation reactions. These 
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reactions are responsible for linking the PG monomers and crosslinking of peptide chains.10,12 The 
resulting mesh-like structure around the cell provides it with structural rigidity. Peptidoglycan 
maintains the shape of the cell and is known to participate in cell division.13 Therefore, the 
peptidoglycan layer is critical for the survival of bacteria and any form of disruption in its 
formation can result in cell lysis.9 
 
 
Figure 1.2. GlcNAc-MurNAc-pentapeptide, an uncrosslinked peptidoglycan monomer  
1.3 Antibiotics targeting the peptidoglycan synthesis 
1.3.1  β-Lactam antibiotics  
 β-Lactams are broad-spectrum antibiotics which include penicillins, carbapenemes, 
cephalosporin and monobactams.8 As the name suggests, this group of antibiotics possess a β-
lactam ring which is crucial for their inhibitory activity. β-Lactams act by inhibiting 
transpeptidation reaction in PG synthesis, which is catalyzed by the enzyme transpeptidase, a type 
of penicillin binding proteins (PBP).14 Transpeptidation is the process of crosslinking the 
pentapeptides from the nascent PG to form a mesh-like structure. Transpeptidase possess a serine 
residue in the active site which acts as a nucleophile and attacks the amide bond between the last 
two D-Ala residues, forming an acyl-enzyme intermediate with the loss of the terminal D-Ala. In 
the second half of the reaction, the amine of a DAP residue from an adjacent pentapeptide attacks 
4 
 
the acyl intermediate to form a new peptide bond, which gives rise to a crosslinked structure 
strengthening the peptidoglycan.9,10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The β-lactam antibiotics possess a strained β-lactam ring which competes with D-Ala-D-
Ala and acts as a substrate for transpeptidase.14 The enzyme generates the acyl-enzyme 
intermediate with the β-lactam ring instead of the pentapeptide D-Ala-D-Ala bond (Figure 1.4).15 
These penicillinoyl adducts then start to accumulate because the active site lacks water to 
hydrolyze them. The site is thus blocked for its substrates, the PG monomers, which are no longer 
utilized.14,15 The construction of peptidoglycan slows down drastically, eventually resulting in 
weakening of cell wall and cell lysis.16 
Nucleophilic attack by transpeptidase 
(TPase) on the penultimate D-Ala of 
nascent PG 
Figure 1.3.  Reaction catalyzed by transpeptidase enzyme in the peptidoglycan synthesis to form 
the D-Ala-m-DAP bond.8 
Acyl-enzyme 
 Intermediate 
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Figure 1.4. Deactivation of transpeptidase by penicillin by forming a penicillinoyl adduct.14  
1.3.2 Glycopeptides 
Vancomycin and teicoplanin are the most successfully employed antibiotics of this class. 
Glycopeptides also inhibit the transglycosylation and transpeptidation reaction in the PG assembly 
process.17 Both vancomycin and teicoplanin are large molecules with a common cyclic 
heptapeptide scaffold. A molecule of vancomycin fits perfectly around the D-alanyl-D-alanine (D-
Ala4-D-Ala5) unit of the muramyl-pentapeptide and gets anchored via hydrogen bonds (Figure 1.5). 
The peptide crosslinking is thus prevented because the substrate is sterically hindered from the 
transpeptidase enzyme. The vancomycin-bound pentapeptide has been identified by X-ray and 
NMR.18 A drawback of glycopeptides is that because of their large structures, the antibiotics have 
poor oral absorptivity and are only effective against Gram-positive bacteria, which lacks the outer 
cell membrane.19 
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Figure 1.5. Prevention of transpeptidation by glycopeptide antibiotics: Interaction of the D-
Ala4-D-Ala5 residues from peptidoglycan with vancomycin through five hydrogen bonds.17 
1.3.3 Fosfomycin 
Fosfomycin is the only antibiotic in clinical use that targets one of the muramyl (Mur) 
enzymes.20 Muramyl A-F are a group of enzymes in the peptidoglycan assembly process which 
catalyze the cytoplasmic steps. MurC, MurD MurE and MurF catalyze the stepwise addition of 
amino acids to form muramyl pentapeptide while MurA and B catalyze the conversion of UDP-
GlcNAc to UDP-MurNAc.10 Inhibition of this reaction stops the supply of MurNAc, which is one 
of the two glycan units forming peptidoglycan. Fosfomycin is a simple epoxypropyl phosphonate 
compound which inactivates MurA. The cysteine residue in the active site of MurA attacks the 
epoxide ring of fosfomycin resulting in a covalent adduct, thus blocking the active site of the 
enzyme (Figure 1.6).21 As a result, the conversion UDP-GlcNAc is inhibited, exhausting the pool 
of PG monomers required to build the peptidoglycan. 
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Figure 1.6. Conversion of UDP-GlcNAc to UDP-MurNAc by MurA and MurB enyzmes. (B) 
Inactivation of MurA by fosfomycin8,21 
1.3.4 Resistance to antibiotics targeting the cell wall synthesis 
Bacteria can adopt various resistance mechanisms against antibiotics such as modifying 
the target enzyme to reduce its affinity for the antibiotic, decreasing cell permeability, destroying 
the antibiotic before it reaches the target and evolving alternate biochemical routes with enzymes 
that are not recognized by the antibiotic.4 In Gram-negative bacteria, resistance to β-lactams is 
offered primarily by enzymes called β-lactamases, which destroy the antibiotic by hydrolyzing the 
β-lactam ring before it reaches the target enzyme.22 In S. pneumoniae and S. aureus, mutations 
result into modified PBPs which have low affinity for β-lactam antibiotics. Bacteria such as species 
of Mycobacterium and Enterococcus have mechanisms which do not employ transpeptidase, the 
target enzyme for penicillins. Instead, L,D-transpeptidase carries out the function of cross-linking 
the peptides using a mechanism different from transpeptidase, rendering the antibiotic ineffective 
in blocking this step.5 
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 Different mechanisms of fosfomycin resistance have also emerged. The antibiotics-
degradation mechanism has been observed to operate in fosfomycin-resistant bacteria. Three types 
of fosfomycin-inactivating enzymes, fosA, fosB and fosX, have been observed. These enzymes 
open the fosfomycin ring by adding glutathione (fosA), L-cysteine (fosB) or H2O (fosX) to it 
before the antibiotic reaches the target.23 In another mechanism, mutation in the genes encoding 
the fosfomycin transporters across the cell was observed, resulting in reduced uptake of the drug.21 
In E. coli and M. tuberculosis, modification of the active site of the target enzyme MurA offers the 
resistance.24 
Resistance to glycopeptides antibiotics is offered by mutation in the target enzyme. The 
five hydrogen bonds formed between D-Ala4-D-Ala5 and vancomycin is responsible for its 
antibiotic action. In vancomycin-resistant enterococci (VRE), the D-Ala5 residue is replaced by D-
lactate, which eliminates the amide linkage forming the H-bond with vancomycin. The PG 
monomer with D-Ala-D-Lac does not interfere with the function of transpeptidase, but the affinity 
of transpeptidase towards vancomycin decreases 1000-fold, allowing the bacteria to survive. In 
some Enterococci, D-Ala5 is replaced by a serine residue, which also results in decreased affinity 
for vancomycin.25 The effectiveness of vancomycin against S. aureus is also decreasing gradually 
owing to resistance mechanism and poor bioavailiblity.19 
The cell wall synthesis machinery is being reviewed for new targets and the efforts to 
develop drugs have met with mixed success. The lysine biosynthesis pathway is one of the 
biochemical routes which supplies the cell wall with mDAP and lysine, the components of a PG 
monomer. This pathway is therefore considered as a target for developing new antibacterial agents 
since no drugs targeting this pathway are currently in clinical use.6,26 
1.4 The diaminopimelate pathway of lysine biosynthesis  
The lysine biosynthesis pathway in bacteria is known as the diaminopimelate (DAP) 
pathway and leads to the production of lysine and meso-diaminopimelate.6 Lysine and its 
biosynthetic precursor DAP are the key components of bacterial cell walls, cross-linking the PG 
monomers.7,27 Lysine also plays an important role in many cellular processes, the ε-amino group 
being important for interaction with other proteins and nucleic acids. Inhibition of enzymes in this 
pathway would result in insufficient production of these components and eventually hinder 
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peptidoglycan synthesis. Since the DAP pathway is absent in mammals, drugs targeting this 
pathway would have minimum toxicity effects on mammalian cells.  
The pathway begins with the conversion of aspartic acid to (S)-aspartate-β-semialdehyde 
(ASA) (Figure 1.7). At this point, it branches out into syntheses of leucine, isoleucine, threonine 
and lysine, also known as the aspartate family of amino acids.28 For lysine synthesis the first step 
is the reaction between ASA and pyruvate which is catalyzed by dihydrodipicolinate synthase 
(DHDPS) to form dihydrodipicolinate (DHDP).29 DHDP undergoes reduction in the presence of 
NADH to form tetrahydrodipicolinate (THDP) catalyzed by dihydrodipicolinate reductase 
DHDPR.30 The cyclic product is then converted to meso-DAP via 3 steps: N-acylation, a 
transimination reaction and epimerization. All the enzymes in this pathway have been extensively 
studied and efforts have been made to design inhibitors of DHDPS, DHDPR, DAP epimerase, N-
acyl transferase and DAP decarboxylase. So far, no inhibitors with high potency have been 
reported for these enzymes.6,31,32 
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Figure 1.7. Diaminopimelate pathway in bacteria26 
1.5 Dihydrodipicolinate synthase: A validated drug target  
Dihydrodipicolinate synthase (DHDPS, E.C. 4.2.1.52) is an enzyme belonging to the DAP 
pathway which catalyzes the formation of dihydrodipicolinate from (S)-aspartate-β-semialdehyde 
and pyruvate. DHDPS has been validated as a drug target by gene knockout experiment. It was 
observed that deletion of the dapA gene in E. coli which encodes DHDPS resulted in cell death.33 
In Mycobacterium smegmatis, the gene encoding aspartokinase, the first enzyme in DAP pathway 
was deleted. The resulting mutant was not viable when deprived of DAP in the culture indicating 
that this pathway and its product DAP are essential for bacterial survival.34 Since then, attempts 
have been made to design new antibacterial agents targeting bacterial DHDPS. This thesis focuses 
on DHDPS from Campylobacter jejuni, a Gram-negative pathogen, which causes gastroenteritis 
in humans. If left untreated, it can lead to more severe conditions such as Guillain-Barré syndrome, 
meningitis and chronic colitis.35  
11 
 
1.5.1 DHDPS mechanism 
The mechanism has been well studied in DHDPS obtained from E. coli. DHDPS follows a 
substituted-enzyme, or ping pong, kinetic mechanism where pyruvate and (S)-aspartate-β-
semialdehyde (ASA) are the two substrates.36 In this type of enzyme mechanism, the enzyme and 
the first substrate bind to form a complex accompanied by the release of the first product. The 
second substrate then binds to this enzyme-substrate complex to release the second product. At the 
end of the reaction, the enzyme is regenerated for another catalytic cycle.37 The mechanism with 
DHDPS is shown in (Figure 1.8) 
 
 
Figure 1.8. Substituted-enzyme mechanism of dihydrodipicolinate synthase 
 
 A catalytic triad consisting of two tyrosine residues and one threonine residue are proposed 
to facilitate the proton exchange required for the mechanism.38 Mutagenesis of any of these three 
residues greatly reduces enzymatic activity. Pyruvate condenses with an active site lysine residue 
forming a Schiff base with the release of a water molecule as the first product.29 The Schiff-base 
is converted to enamine by general base catalysis. Binding of the second substrate ASA to this 
enamine leads to a condensation reaction after which the second product, which was believed to 
be (4S)-3-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinnic acid is expelled. This unstable cyclized 
product was shown to undergo dehydration spontaneously in solution.39,40 The role of the catalytic 
triad and a detailed molecular mechanism is discussed in the next section.  
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1.5.2 The tetrameric structure of DHDPS 
 
Figure 1.9. Homotetramer of DHDPS from C. jejuni with lysine (yellow spheres) in the 
allosteric site. (PDB: 4M19). 
DHDPS exists as a homotetramer in most bacterial species examined (including C. jejuni) 
with the exception of S. aureus where the enzyme has a dimeric form.41–44 The homotetramer can 
be described as a loose dimer of two tightly-bound dimers. The significance of the tetrameric 
structure towards enzyme activity has been explored before by disrupting the enzyme at the loose 
interface and comparing the activity of the resulting dimer with wild-type enzyme. The dimeric 
form of E. coli DHDPS showed decreased catalytic efficiency whereas the dimer from M. 
tuberculosis was as active as its tetramer.45,46 
 Each subunit of the tetramer consists of a (β/α)8 barrel in which eight β-strands are 
arranged in a circular structure to form a barrel which is surrounded by 8 helices. The active site 
is harbored within these folds.44 The allosteric site of the enzyme is present at the tight dimer 
interface.47 
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1.5.3 Active site 
 
 
 
 
 
 
 
 
 
 
 
 
The active site in DHDPS from C. jejuni is similar to that from E. coli. The two species 
share 37% sequence identity, and all the important residues from active site and allosteric sites are 
conserved.48 The enzyme mechanism has been studied in detail in E. coli using site directed 
mutagenesis and crystallography.44 The structural alignment of DHDPS tetramers from E. coli and 
C. jejuni also highlights the similarities in the placement of the conserved residues active site and 
allosteric site.49 The reaction is initiated by condensation of an active site lysine residue, which is 
K166 in C. jejuni, with pyruvate to form a Schiff base which tautomerizes to enamine. The proton 
transfer during the course of the reaction is proposed to be facilitated by a catalytic triad made up 
of highly conserved tyrosine (Y137 and Y111') and a threonine (T47).38 For each active site, the 
Y111' residue from the neighboring monomer completes the triad (Figure 1.10). 41 The second 
substrate ASA condenses with the enamine, the product of which cyclizes into (4S)-hydroxy-
2,3,4,5-tetrahydro-(2S)-dipicolinic acid (HTPA)  via transamination.40 This unstable heterocyclic 
product then spontaneously dehydrates to (S)-2,3-dihydropyridine-2,6-dicarboxylate (DHDP) 
(Figure 1.11).  
 
Lys166 
Tyr137 
Tyr111' 
Thr47 
Figure 1.10. The catalytic triad (Tyr111', Tyr137 and Thr47) and the lysine residue (Lys166) 
from the active site of C. jejuni DHDPS (PDB: 3LER). Tyr111' (green, primed) belong to the 
adjacent monomer.  
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Figure 1.11. Reaction catalyzed by DHDPS 
1.5.4 Allosteric site and lysine inhibition 
Lysine is a feedback inhibitor of DHDPS in Gram-negative bacteria and plants while 
Gram-positive bacteria are weakly inhibited or completely insensitive to lysine.42–44,50 Within the 
lysine-sensitive species, there is a variation in the degree of inhibition as well as the reported 
inhibitory mechanism. C. jejuni DHDPS is more sensitive to lysine (IC50 = 65 µM) compared to 
E. coli DHDPS (IC50 = 200 µM).
48 Inhibition by lysine was cooperative in nature where the binding 
of the second lysine molecule was 105 times stronger than the first.51 The cooperativity of lysine 
binding was, however, only taken into account in recent DHDPS kinetic studies with Vitis 
vinifera50 and C. jejuni48 DHDPS. The degree of cooperativity in ligand binding is measured by 
calculating the Hill (cooperativity) coefficient. A value greater than 1 indicates positive 
cooperativity, meaning binding of one ligand increases the binding affinity of enzyme for the next 
ligand. The Hill coefficient for C. jejuni DHDPS was greater than 2, indicating that binding of 
lysine across the two allosteric sites was cooperative.49 However, the crystallographic data 
provided no evidence of any major structural changes after lysine binding.41 The mechanism of 
cooperativity is still not completely deduced and probably more than one subtle change in the 
enzyme is responsible for the communication from the allosteric site. The results obtained after 
incorporating the cooperativity coefficient in the kinetic equation showed that lysine was an 
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uncompetitive partial inhibitor with respect to pyruvate and mixed partial inhibitor with respect to 
ASA.48 These models of inhibition implied that lysine preferentially binds to the enzyme-pyruvate 
complex over the ASA bound form.41,48  
Across all the lysine-sensitive species, the allosteric site is located at the tight dimer 
interface of the homotetramer. Residues from both monomers of the tight dimer make up the 
allosteric site where two lysine molecules are bound. Crystal structures of DHDPS from different 
plant and bacterial species and site-directed mutagenesis studies helped to reveal important 
residues in the allosteric site. Studies of E. coli DHDPS showed that the two highly conserved 
tyrosine residues Tyr106-Tyr107 were possible links between the active site and the allosteric site. 
Conly et al.41 recently reported the crystal structure of lysine-bound DHDPS from C. jejuni which 
did not reveal any changes in the architecture of the active site. However, lysine binding introduced 
domain movements in each monomer as well as changes in the cavity volumes of both the sites 
which could be a contributing factor to the allostery. A comparison of the lysine-bound tetramer 
to the free enzyme helped to show the importance of Tyr110 and Tyr111 as a linker between the 
active and allosteric site. Tyr110 forms a hydrogen bond with the carboxylate group of lysine 
inhibitor while the catalytic triad of the adjacent monomer is completed by Tyr111. These residues 
were therefore established as potential links between the active and allosteric sites. 
The importance of Tyr110 was demonstrated by the mutant Y110F where the tyrosine110 
was replaced by phenylalanine, which could not make a hydrogen bond with the carboxyl group 
of lysine. This mutant was drastically less sensitive to lysine (IC50 = 40 mM) compared to wild 
type (IC50 = 65 µM).
49 Apart from Tyr110, His56 and His59 also play important roles in the 
allosteric site. The binding of lysine to the pyruvate-bound enzyme results in a change in the 
positions of His56 and His59. Site-directed mutagenesis of these residues demonstrated the 
significance of these residues. The crystal structure showed that His59 is in a position to form a 
hydrogen bond with the ε-amino group of lysine (Figure 1.12). Mutants of His59 were designed 
to disrupt this hydrogen bond and observe its effects on the strength of lysine inhibition. Mutation 
of His59 to asparagine and alanine decreased the binding affinity of lysine 10-fold and 40-fold 
respectively, supporting the hypothesis that polar contacts with this histidine residue are important 
for allosteric inhibition. Mutation of His56 to asparagine and alanine resulted in three and five fold 
decrease in the binding affinity, which was consistent with the fact that His56 does not form any 
polar contacts directly with the lysine inhibitor.   
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Figure 1.12. Allosteric site of C. jejuni DHDPS with two lysine molecules bound (yellow). 
Green (primed) and blue represent two adjacent monomers and black dashed bonds 
represent polar contacts. (PDB: 4M19).41 
  
K166 
Y110 
Y111' 
T47 
H59 
H56 
E88 
A52 
H59' 
H56' 
Y110' 
E88' 
A52' 
K166' 
Y137' 
T47' 
Y111 
 
Y137 
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1.6 Inhibitors of DHDPS 
1.6.1 Inhibitors targeting the active site 
a) Substrate analogues 
 
Figure 1.13. Pyruvate analogues as inhibitors of DHDPS.39 
 The pyruvate analogues in Figure 1.13 were shown to be competitive inhibitors with 
respect to pyruvate, for E. coli DHDPS.39 The analogues varied in the chain length and their 
inhibition constants (Ki) were useful to gain more knowledge about the active site geometry. The 
compound 3-fluoropyruvate (1.1) had a Ki similar to the Km of pyruvate suggesting that the 
substitution by fluorine was accommodated in the active site. Increasing the chain length resulted 
in weaker binding. The Ki for 2-ketobutyrate (1.2) was 4-fold higher than that of pyruvate. The Ki 
for glyoxalate (1.3) which is a smaller compound was also 10-fold lower than that of pyruvate, but 
no further data or explanation could be found in the literature.39  
ASA analogues were synthesized based on the structure of the aldehyde form and the 
hydrate form, the latter of which is believed to be predominant in aqueous solution. It was also 
proposed that the hydrate may cyclize and exist in the form of a cyclic lactol.52 All these forms 
were considered for synthesizing DHDPS inhibitors. Glutamic acid (1.5) was found to be 
uncompetitive inhibitor and aspartic acid (1.4) was a mixed inhibitor. These patterns indicate that 
these acid analogues bind in the allosteric site instead of the active site. Homoserine lactone (1.7) 
and 2-aminocyclopentanone (1.8) both displayed non-competitive inhibition, indicating that they 
are not a substrate analogue.53 Another substrate analogue succinic semialdehyde (1.6) in which 
the amine from ASA was replaced by hydrogen also showed weak inhibition indicating that this 
strategy is not very promising for synthesizing DHDPS inhibitors.6,39 
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Figure 1.14. Analogues of ASA as inhibitors of DHDPS.53 
b) Product analogues 
 
Figure 1.15. Analogues of DHDP as weak inhibitors of DHDPS.54 
Based on the structure of DHDP, heterocyclic inhibitors such as 1.9 and 1.10 were 
synthesized and found to be weak inhibitors of E.coli DHDPS.54 However, since DHDP is formed 
by dehydration of HTPA40, it was proposed that analogues of HTPA might prove to be better 
inhibitors. Analogous heterocycles with an oxygen substituent at carbon 4 were synthesized. 
Dimethyl chelidamate and chelidamic acid (1.13) both were moderate uncompetitive inhibitors of 
DHDPS.54 Both these compounds were also tested against other bacterial species and found to be 
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potent against E. coli, MRSA and M. tuberculosis.55 The sulfur-containing analogues 1.11 and 
1.12 were all weak inhibitors.54 
 
Figure 1.16. Tetrahydrodipicolinate analogues as moderate inhibitors of DHDPS.54 
c) Enzyme-bound intermediate analogues 
Recently, the acyclic enzyme-bound intermediate from the DHDPS catalyzed reaction was 
used as a template for analogous compounds as inhibitors (Figure 1.17). The first two compounds 
synthesized in this series were 4-oxo-heptenedioic acid and the corresponding ester (1.8) which 
showed irreversible inhibition.56 The bis(oxime-ester) (1.16), bis(keto-ester) (1.17) and  bis(keto-
acid) (1.19) were synthesized as conformationally constrained analogues.57 These compounds 
performed better than the product analogues and showed time dependent irreversible inhibition. 
The bis(keto-acid) (1.18) and 1.16 were selected as lead compounds and await further studies.57  
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Figure 1.17. Moderately active DHDPS inhibitors based on the structure of enzyme-bound 
intermediate. 
To summarize, the active site-directed inhibition is not a very promising strategy to 
synthesize potent inhibitors of DHDPS. The pyruvate and ASA analogues were weak inhibitors of 
DHDPS. The chelidamic acid and enzyme intermediate analogues did show moderate activity but 
no further data has been reported. 
1.6.2 Allosteric inhibitors 
Since the validation of DHDPS as a drug target, attempts have been made to design 
inhibitors of this enzyme, targeting the active site. These compounds showed only moderate to 
weak inhibition, suggesting a need to adopt a different strategy for designing inhibitors.43 The 
kinetic studies of mutants of DHDPS gave information about the allosteric site and lysine binding. 
As a step toward synthesizing new inhibitors, lysine analogues were tested to see the effect of 
small structural changes on allosteric inhibition. Interestingly, the two analogues, α-methyl-DL-
lysine and L-thialysine performed poorly as inhibitors compared to lysine.49 This result indicated 
that the allosteric site is very specific to lysine. It was proposed that having a methyl substituent at 
the α-carbon hinders the binding of second lysine molecule thereby decreasing the inhibitory 
effect. But even simple heteroatom substitutions seem to affect the inhibition as observed with L-
thialysine inhibitor. Substituting one of the carbons with sulfur lowered the pKa of the ε -amino 
group which seems to affect the degree of inhibition. These results gave some insight on the 
requirements for a good inhibitor. First, the binding of both the lysine molecules is important for 
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achieving maximum inhibitory effect and second, the pKa of lysine side chain is crucial. This amino 
group forms hydrogen bond with His59 but the exact role of this residue in allosteric inhibition is 
yet to be understood completely. 
 
 
Figure 1.18. Lysine analogues as allosteric inhibitors of DHDPS 
Based on these hypotheses, a ligand which could mimic the binding of lysine in allosteric 
site could be an inhibitor. There were no leads on building an inhibitor better than lysine until 
Phenix and Palmer51 reported their findings from ITC studies that binding of the first lysine 
molecule induces favorable changes in enthalpy and entropy of binding, which results in tighter 
and almost simultaneous binding of the second lysine molecule. This result formed the basis of 
designing an inhibitor which would mimic the synchronous binding of a pair of lysine molecules 
in the allosteric site. The new inhibitor, (R,R)-bislysine was thus formed by joining two (S)-lysine 
molecules with a two carbon bridge separating the -carbon atoms.49 
1.7 Bislysine synthesis and activity  
Synthesis of (±)-bislysine was achieved by bisalkylation of dimethyl 2,5 
bis([(tertbutoxy)carbonyl]amino)hexanedioate 10 (Scheme 1.1). Adipic acid was converted to 10 
using reported procedures by Sheehan.58 It was then alkylated using 1-bromo-4-chlorobutane as 
the electrophile. The reaction proceeds with 19% yield generating a mixture of stereoisomers of 
the bisalkylated product. The meso:racemate ratio was 1:5 and the two were separated using flash 
column chromatography. The racemic mixture was transformed into corresponding phthalimides, 
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separated using chiral HPLC and deprotected to give (R,R)- and (S,S)-bislysine. (R,R)-bislysine, 
as predicted, proved to be the most potent inhibitor for DHDPS with Ki = 0.2 µM.
59 
 
 
Scheme 1.1 
Reagents: (a) SOCl2, 80 °C, 3 h; (b) Br2, 500 Watt, 12 h, 80 °C; (c) MeOH, 14 h, rt; a-c yield 87%; 
(d) potassium phthalimide, DMF, 90 °C, 2 h, 90%; (e) 1:1 48% HBr:AcOH, 14 d, 115 °C, 96%; 
(f) AcCl, MeOH, 2 h, 65 °C, quant. yield; (g) DIBOC, TEA, THF, 14 h rt, 3 h 50 °C, 72%; (h) 1-
bromo-4-chlorobutane, LDA, THF/10% HMPA, 1 h, -78 °C, 19%; (i) potassium phthalimide, 
DMF, 90 °C, 2 h, 50%; (j) 1:1 48% HBr:AcOH, 3 d, 115 °C, AG 50W-X2, 88%. 
 
A crystal structure of (R,R)-bislysine bound to DHDPS was also obtained, confirming the 
conformation of the compound in the allosteric site (Figure 1.19). Bislysine binds to the enzyme 
similar to lysine exactly as predicted, restoring all the essential polar contacts with the surrounding 
residues. However, kinetics studies with site-directed mutants showed major differences. The 
mutants Y110F, H59N, H59A showed comparable activity to wild type with bislysine with IC50 
values ranging from 0.2-0.6 µM for all the mutants whereas they were insensitive to lysine 
inhibition. This indicates that the absence of hydrogen bonds does not affect the inhibitory activity 
as strongly as it does for lysine and that the allosteric site can probably tolerate modifications in 
the structure of the inhibitor. Whether these residues are important for inhibition as predicted based 
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on crystallography data or only assist binding of an inhibitor is not clear. Also, the partial inhibition 
showed by lysine and bislysine is not yet explained. These results from mutagenesis studies 
suggest that a lot is unknown about the mechanism of allosteric inhibition in DHDPS. 
 
Figure 1.19. Allosteric site of C. jejuni DHDPS with (R,R)-bislysine (yellow stick) (PDB: 
5F1V). Green (primed) and blue represent two adjacent monomers. Black dashed bonds 
represent polar contacts.59  
Even though R,R-bislysine is an excellent inhibitor of DHDPS, it only represents the ideal 
inhibitor design. The results obtained from lysine analogues suggest that any modification 
introduced in this structure will have a negative effect on its activity. It is important to test a range 
of diverse compounds as inhibitors with minor to major structural modifications. With four 
positively charged amino groups and two carboxylic groups, the compound is not very lipophilic 
which can prevent it from crossing the cell membrane. Therefore, the compound does need certain 
modifications in order to overcome the structural drawbacks and evolve as a drug-like molecule. 
The bislysine structure, however successfully proved the hypothesis put forth by Phenix and 
Palmer51, as described above and can be used as a core structure to synthesize other allosteric 
inhibitors for this enzyme. 
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2  RESEARCH OBJECTIVES 
 
During previous studies on allosteric inhibition of DHDPS, some important information 
relevant to the strength of inhibitors was revealed,49,59 which is summarized below:  
 L-Thialysine was less effective in inhibiting the enzyme compared to its natural 
inhibitor L-lysine, putatively because of the lower pKa of thialysine.  
 The synthetic inhibitor R,R-bislysine was established as the most potent inhibitor of 
DHDPS yet studied. 
 X-ray crystallography and site-directed mutagenesis studies showed that the hydrogen-
bond between His59 and the inhibitor is crucial for inhibition.    
Therefore, an important objective of this research was to synthesize a group of inhibitors 
which would demonstrate the effects of varying structural features such as the side chain, the pKa 
of the side chain amine, and its ability to form a hydrogen-bond with His59. This information 
could be used to synthesize more potent and efficacious allosteric inhibitors.  
Lysine is the natural allosteric inhibitor of DHDPS. Therefore, other amino acids could 
also be used to study the effects of modifications in the side chains. Since bislysine mimics the 
lysine pair bound in the allosteric site, the polar contacts made by lysine are retained in the 
bislysine-bound enzyme as proven by the crystal structure.59 Thus, the implications of structural 
modifications would be similar on both 'monomeric' analogues and bislysine analogues. Some 
lysine analogues could be purchased, but others can be synthesized in well-established methods. 
Bislysine analogues could be obtained using a synthetic approach similar to that used for bislysine, 
and involving bisalkylation of a protected 2,5-diaminoadipate using different electrophiles. Since 
this reaction was common to the synthesis of all the inhibitors, its optimization was important to 
obtain maximum yield of bislysine and other inhibitors. Therefore, the factors affecting the 
bisalkylation reaction were also examined.  
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3 RESULTS AND DISCUSSION 
3.1 Alkylation reactions of α-amino esters. 
The alkylation of protected 2,5-diaminoadipate was a crucial step in the bislysine synthesis 
because of its outcome - the bisalkylated product which can be separated into diastereomers. This 
alkylation is the point where the synthesis can be diverted into varying target intermediates by 
using different electrophiles, which can be elaborated further into bislysine analogues. Therefore, 
the low yield of this reaction was of great concern and required a detailed study. For any reaction 
involving a stereogenic center, the stereoselectivity, along with the yield, needs to be optimized to 
get the desired isomer in adequate quantity. In the reported bislysine synthesis, the reaction favored 
formation of the desired racemic mixture as the major product; therefore improving the 
bisalkylation yield was prioritized over optimizing the stereochemical outcome of the reaction.  
The bisalkylation proceeds via enolate formation from an α-amino ester which attacks the 
alkyl halide to form the C-alkylated product. Reactions involving α-amino ester enolates have been 
known to proceed in good yield. For example, Bartlett and Barstow60 presented a study on the 
ester-enolate Claisen rearrangement of allylic esters derivatives where the influence of various 
factors such as additives, protecting groups, and α-substituents was investigated. The first step in 
this reaction is the formation of an α-amino ester enolate followed by silylation. The silyl enolate 
then rearranges at elevated temperature (55 °C) to give the rearranged product. The enolate 
formation was carried out in different conditions as described in Table 3.1. It was concluded from 
this study that the best condition for the deprotonation step was the ‘standard condition’, in which 
LDA was used as a base in tetrahydrofuran (THF) as solvent at −75 °C (entry 1). 
Use of hexamethylphosphoric triamide (HMPT) as a cosolvent or 
tetramethylethylenediamine (TMEDA) as an additive lowered the yield and stereoselectivity 
(Entry 3 and 4). Reaction in diethyl ether instead of THF gave a low yield with no effect on the 
stereoselectivity (entry 2). Adding magnesium chloride also did not offer any advantage in yield 
or stereoselectivity (entry 6). 
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Scheme 3.1 
 
Table 3.1. Influence of varying reaction conditions on Claisen rearrangement described in 
Scheme 3.160 
Entry conditions Yield % 3a:3b 
1 
2.1 eq. LDA in THF, 10 min. followed by 
silylation (standard) 
60-65 9 
2 Ether solvent 45 10 
3 20% HMPT/THF solvent 51 4 
4 2.2 equiv. TMEDA included with base 36 Not determined 
5 KDA as base 0 - 
6 1.1 equiv. MgCl2 included with ester 42 10 
7 
Bromomagnesium isopropylcyclohexylamide 
as base 
29 2 
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An elaborate study on C-alkylation of peptides was also carried out by Seebach61 where 
deprotonation was achieved using LDA as base. Alkylation of dipeptides, polypeptides as well as 
large cyclic peptides was successfully performed with high yield and diastereoselectivity. It was 
observed that adding lithium salts such as LiCl or LiBr after deprotonation with LDA enhanced 
the yield without any epimerization at the stereogenic centers. The α-methylation of a β-
aminobutyric acid derivative in THF proceeded with 73% yield; while in presence of LiCl, the 
yield increased to 87% (Scheme 3.2). In the absence of LiCl, the reaction mixture was 
heterogeneous and required warming to 0 °C to complete the methylation. Adding LiCl resulted 
in increased solubility of the deprotonated peptide by forming mixed aggregates, allowing the 
reaction to proceed at −78 °C. Methylation at multiple sites in large cyclic peptides was also 
achieved in high yield using lithium chloride. 
 
 
Scheme 3.2 
Another strategy used to synthesize α-amino acids was using Scholkopf’s alkylation 
method where stereoselective alkylation of a 2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine 
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(bis-lactim ether) was achieved using nBuLi. The alkylated bis-lactim ether was then subjected to 
a mild acid hydrolysis to obtain α- substituted amino acids. This method was exploited to 
synthesize α,α' substituted bridged amino acids For example, bisalkylation of Scholkopf's bis-
lactim ethers where the two lactim rings were separated by a 5-carbon bridge with the two 
stereogenic centers α and α' was achieved using nBuLi as base (Scheme 3.3).62 The alkylated 
product was obtained in 73% yield when allyl bromide was used as alkylating reagent. This 
strategy was used to synthesize α-amino acids.  
 
Scheme 3.3 
To summarize, enolates of α-amino ester have previously been shown to be alkylated using 
LDA as the base and THF as the solvent. The Scholkopf’s alkylation method was appealing since 
it could allow us to synthesize more bridged inhibitors. However, the choice of electrophiles in all 
these reactions was restricted to reactive species such as methyl iodide and allyl halides. The effect 
of lithium salts on the alkylation yield was also noteworthy and thought to be a promising strategy 
for improving the yield of bislysine synthesis. 
3.2 Examination of conditions for the bisalkylation reaction  
According to the reported procedure of the bisalkylation of the protected 2,5-
diaminopimelate 10,59 an enolate was generated using LDA as the base in THF with HMPA as a 
cosolvent at −78 °C (Scheme 1.1). After 1 hour, an additional 2 eq. nBuLi was added followed by 
1-bromo-4-chlorobutane. The reaction mixture was stirred at the same temperature for 2 hours and 
then quenched with aqueous ammonium chloride solution. With this reaction condition, 30% of 
the starting material was recovered with 19% bisalkylation yield. When this procedure was used 
for alkylation with propargyl bromide and (2E)-1,4-dibromo-2-butene, the crude was obtained as 
a complex mixture of impurities. The pure product was isolated by column chromatography with 
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great difficulty. Therefore, the existing reaction conditions were reexamined using the electrophile 
propargyl bromide (Table 3.2). The racemate:meso ratio was calculated based on the isolated yield 
for all the bisalkylation reactions. The enolate was formed at −78 °C in THF for all the entries. 
The use of reported conditions gave 23% yield with 2.8:1.0 ratio of racemate:meso (entry 1). Only 
15% of the starting material could be recovered. In the following steps (entry 2 and 3), HMPA and 
the extra equivalent of nBuLi was excluded respectively. The exclusion of HMPA increased the 
yield to 30% and also led to a higher recovery of starting material. It was clear that HMPA and the 
extra nBuLi was not required to obtained the best possible yield and a simplified procedure could 
be used. In another attempt to improve bisalkylation yield, the reaction mixture was stirred for 10 
hours at −78 °C (entry 4) after the addition of the electrophile but the extended time did not have 
any effect on the reaction yield. For the following alkylations with different electrophiles, the 
modified procedure, with 4.5 equivalents of LDA, without HMPA was used. 
 
Table 3.2. Bisalkylation: Scope of the reaction with propargyl bromide as the electrophile 
Entry Reaction condition 
Bisalkylation 
yield 
Racemate:meso 
Starting material 
recovered 
1 
4.5 + 2 eq. LDA, HMPA 
−78 ºC, 2 h 
23% 2.8:1.0 15% 
2 
4.5 + 2 eq. LDA, −78 ºC, 
 2 h 
30% 2.5:1.0 22% 
3 
4.5 eq. LDA, 
−78 ºC, 2 h  
32 % 2.5:1.0 25% 
4 
4.5 eq. LDA,  
−78 ºC, 10 h after 
alkylation 
32% 2.4 :1.0 22% 
 
3.2.1 Reactions with different electrophiles 
Since it was important to synthesize lysine-dimer analogues, the bisalkylation was carried 
out with different electrophiles which were strategically selected so that they could be further 
transformed into inhibitors. The electrophiles chosen were allyl bromide, propargyl bromide and 
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(2E)-1,4-dibromo-2-butene, all of which are more reactive than aliphatic halides. The adjacent π-
electrons in these halides stabilize the transition state of the SN2 reaction by conjugation, increasing 
the rate of the reaction. The electrophile (2E)-1,4-dibromo-2-butene was important because 
replacing the bromides of the bisalkylated compound with phthalimide moieties followed by 
hydrolysis would result in the formation of bislysine with a higher yield than the existing route.  
 
Table 3.3. Comparison of bisalkylation reaction yields using various electrophiles  
 
Entry 
Electrophile, 
R-Br 
Bisalkylation 
yield (%), 
Racemate: 
meso 
Monoalkylation 
Yield (%) 
Starting 
material 
recovered 
(%) 
1  12 4.6:1.0 none 39 
2  11 6.3:1.0 18 39 
3  28 5.2:1.0 22 28 
4 
 
32 2.5:1.0 17 25 
5 
 
< 5  none 22 
 
As expected, the reaction proceeded with higher yield with propargyl bromide and allyl 
bromide as electrophiles. However, a considerable amount of starting material was recovered 
along with monoalkylated product. The reaction with 1-bromo-4-chlorobutane as electrophile gave 
the bisalkylated product in 12% yield (Entry 1). The electrophile (2E)-1,4-dibromo-2-butene, 
which was expected to perform better than 1-bromo-4-chlorobutane did not show any 
improvement in the reaction yield. The reaction gave 11% yield, again with a high amount of 
starting material recovery as well as 18% monoalkylated product (entry 2). However the 
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racemate:meso ratio was slightly higher (6.3:1.0) compared to entry 1. Allyl bromide and 
propargyl bromide gave 28% and 32% yield; however, more than 20% starting material was 
recovered. For all the reactions, the products showed the same pattern on TLC and eluted in the 
same sequence, starting with the minor meso-isomer, then the racemate, followed by the 
monoalkylation product. The starting material was eluted at the end. The racemate and meso were 
confirmed by HPLC for 1-bromo-4-chlorobutane and (2E)-1,4-dibromo-2-butene. The reaction 
with 4-nitrobenzyl bromide (entry 5) proceeded with the formation of many impurities which co-
eluted with the product. This made it difficult to isolate the product (or the starting material) in a 
pure form. The presence of product was confirmed by proton NMR, where all the desired peaks 
were observed. The sequence of elution for the products of 4-nitrobenzyl bromide reaction was 
not the same as observed for the first four electrophiles. Therefore, it was not possible to conclude 
if the product was the racemate or the meso-compound. The racemate:meso ratio also decreased 
for propargyl bromide while a higher ratio is observed for the first three electrophiles. For all the 
electrophiles, the racemate was the major product.  
3.2.2 Enolate formation and stability 
The conversion of ester to enolate was confirmed by NMR. After adding the starting material to 
the LDA- THF mixture, the reaction was stirred for 4 h during which the aliquots of reaction 
mixture were quenched with D2O and extracted with EtOAc. The organic layer containing the 
deuterated starting material was collected, solvent was removed and the residue was dried under 
vacuum. If the ester was converted to enolate then quenching with D2O would result in replacement 
of α- hydrogen with deuterium, resulting in a diminished proton peak at δ 4.31.  
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Figure 3.1. Overlay of 1H NMR of fractions 10e, quenched at time intervals as shown in the 
figure. ‘Control’ represents the fraction quenched with H2O.   
The integration of the six methyl ester hydrogens (δ 3.74) was used as internal standard to 
observe the loss of proton signal of the α-hydrogens (δ 4.31) after quenching with D2O (Figure 
3.1). The loss of signal (from ~1.7 to ~0.5) after only 30 minutes indicated that enolate was 
certainly generated within 1 hour of adding LDA. Although the conversion was not 100%, the 
reaction yield remained unchanged when the enolate generation time was extended to 10 h (Table 
3.4, entry 2 and 5). 
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Figure 3.2. Enolate formation by LDA can result in complexes (10a and 10b) in which the 
internal proton is retained, and returned to the substrate after quenching. The acidic 
hydrogens are shown in red.  
The enolates formed by amide bases like LDA have been known to revert back to the 
protonated state by the process called "internal proton return" (Figure 3.2).61,63 After the 
deprotonation of the starting material, diisopropylamine is regenerated which is believed to 
coordinate with the lithium enolate. This amine-lithium enolate complex brings the amine proton 
close enough to the π-electrons of the enolate to reprotonate it. Any electrophile or a deuterated 
quenching agent added at this point does not result in alkylation or deuterated product; simply 
because the rate of "proton return" is faster. Hence, a complete disappearance of the α- proton was 
not observed in the above experiment. This phenomenon also explains the high recovery of starting 
material and low bisalkylation yield. Seebach61 has successfully demonstrated that the internal 
proton return can be avoided by adding an extra equivalent of nBuLi after the enolate formation. 
The additional nBuLi reacts with the regenerated diisopropylamine to form more LDA. This 
procedure was successfully used previously in our laboratory59 for the bislysine synthesis. 
However, adding extra nBuLi results in a mixture of LDA and enolate. The remaining LDA may 
react with electrophile or the product and result in a completely different product or a mixture of 
products at the end of the reaction. This is perhaps the reason why the method did not work well 
in the above reactions with electrophiles such as propargyl bromide.  
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Table 3.4. Effect of longer enolate- generation time on bisalkylation yields 
Entry Reaction condition Enolate time electrophile Bisalkylation yield  
1 
4.5 + 2 eq. LDA, 
−78 ºC, 2 h 
1 h  10%  
2 4.5 + 2 eq. LDA, -78 ºC 10 h  10%  
3 
4.5 eq. LDA, 
-78 ºC, 2 h 
1 h 
 
32%  
4 4.5 eq. LDA −78 ºC, 10 h 
 
28%  
5 4.5 + 2 eq. LDA −78 ºC 10 h 
 
30%  
 
3.2.3 Solvent and additives effect 
Although all the reported procedures for the formation of amino ester enolates used THF 
as a solvent, the bisalkylation was also carried out in other less polar solvents (Table 3.5). The 
electrophile chosen for this study was propargyl bromide, since it gave maximum yield for 
bisalkylation with the standard conditions. The starting material was insoluble in diethyl ether, 
dimethoxyethane (DME) and toluene at –78 °C. The solubility was also checked at elevated 
temperature by slowly raising it up to –20 °C. When HMPA was added, the precipitate dissolved 
giving a clear yellow solution. However, for all the three solvents, the reaction proceeded in < 20% 
yield, the lowest yield being 10% with toluene (entry 4). The aggregated states of enolate formed 
with THF are seemingly aiding in the alkylation.  
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Table 3.5. Effect of varying solvents on bisalkylation yield 
 
Entry additive solvent 
Bisalkylation 
yield (%) 
1 HMPA THF 23 
2 HMPA  Diethyl ether 15 
3 HMPA DME 14 
4 HMPA 1:1 THF: DME 15 
5 HMPA Toluene 10 
 
Table 3.6. Effect of lithium chloride on the bisalkylation yield 
Entry Electrophile additive 
Bisalkylation yield 
(%) 
Racemate:meso 
1 
 
- 32 2.5:1.0 
2 
 
LiCl (6 eq.) 29 2.3:1.0 
4  - 12 4.6:1.0 
5  LiCl (6 eq.) 11 5.5:1.0 
 
As described in section 3.1, using lithium chloride in alkylation reactions of amino acids 
increased the yield of reaction by 30%. Expecting a similar effect, 6 eq. of lithium chloride (1M 
in THF) solution was added to the LDA solution along with the starting material (Table 3.6). After 
one hour of enolate formation, the reaction mixture was stirred at −78 ºC for 10 hours and then 
quenched with ammonium chloride solution. During the reaction, TLC was recorded at the 
intervals of 2, 4 and 8 hours for a parallel reaction which did not show any change over the course 
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of the reaction. Indeed, the isolated yield was 29% for the reaction with propargyl bromide (entry 
2) and 11% with 1-bromo-4-chlorobutane (entry 4).  
In conclusion, the bisalkylation reaction proceeded in low yields for all the electrophiles. 
The only factor affecting the yield was the reactivity of the electrophiles used. The effect of the 
additives HMPA and LiCl on either yield or stereochemistry was not very significant in the 
experiments described above. Therefore, it was difficult to make any conclusions about the 
plausible factors in the reaction procedure which could affect the yield. For synthesizing the dimer-
analogues, the modified procedure, without HMPA and excess LDA was used. 
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3.3 Design and synthesis of allosteric inhibitors 
As described in Section 1.6, there have been many attempts to design inhibitors targeting 
the active site of DHDPS. Compounds which were substrate analogues (1.1-1.3) or transition state 
analogues (1.16 and 1.19) proved to be only moderate to weak inhibitors. The synthesis of 
allosteric inhibitor (R,R)-bislysine put a spotlight on previously overlooked allosteric site of 
DHDPS and opened the door to a new class of inhibitors which would mimic the ‘lysine dimer-
like’ framework. Analogous compounds of lysine and bislysine were synthesized by keeping the 
amino acid backbone intact and replacing the lysine side chain with different moieties.  
3.3.1 Lysine analogues 
Novel lysine analogues were synthesized as shown in Scheme 3.4 and Scheme 3.5 using diethyl 
acetamidomalonate (DEAM) as starting material. DEAM has been used to synthesize α-amino 
acids previously.64,65 Two electrophiles, (2E)-1,4-dibromo-2-butene and propargyl bromide were 
used for C-alkylation of DEAM, leading to two different lysine analogues. For the synthesis of 16, 
the enolate was generated using 10% NaOH as base, following the procedure by Roduit and 
Wyler.66 (2E)-1,4-dibromo-2-butene was used as electrophile to obtain C-alkylated compound 14 
in 44% yield. The amino group was introduced by nucleophilic displacement of the remaining 
allylic bromide with phthalimide in 45% yield using the procedure described previously for 
bislysine synthesis.59 The phthalimide was then hydrolyzed to the amine in refluxing aqueous HCl 
for 3 days, which also removed the ester and amide protecting groups and resulted in 
decarboxylation to give the desired amino acid 89% yield after ion exchange chromatography. 
For the synthesis of triazole 20, cesium carbonate was used to generate the enolate from 
DEAM in acetonitrile, which was then reacted with propargyl bromide as the electrophile67 with 
mild heating for 16 h, resulting in 17 in 88% yield. Apart from an increase in the yield, the CsCO3 
procedure was advantageous because of the simplified reaction procedure and workup, compared 
to the procedure described for synthesizing 14. However with allylic electrophiles, the reaction 
has been shown to proceed with < 50% yield.68 With (2E)-1,4-dibromo-2-butene, the reaction did 
not show much progress in my hands even after refluxing for 24 h and 70% of starting material 
was recovered. The alkyne was then converted to a 1,2,3-triazole using a procedure described 
previously with some modifications.69 This so-called "Click" reaction, a copper catalyzed azide-
alkyne cycloaddition using benzyl azide, afforded the corresponding 1-benzyl-1H-1,2,3-triazole 
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18 in moderate yield. Hydrogenolysis of the benzyl group using H2 and palladium hydroxide 
proceeded smoothly to generate 19, the 1H-1,2,3-triazole. The last step was the acid hydrolysis of 
amide and ester groups accompanied by decarboxylation to the monocarboxylic acid as above. 
 
 
Scheme 3.4 
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Scheme 3.5 
3.3.2 Bislysine analogues 
The bislysine analogues were synthesized using a similar procedure to that described 
previously.59 The BOC-protected dimethyl ester of 2,5-diaminoadipate (10), synthesized as 
described in Scheme 1.1was used as the starting material to carry out bis-alkylation reactions. LDA 
(4.2 eq.) was used to generate enolate after which the desired electrophiles were added to obtain 
the bisalkylated product. The alkylation products were obtained as mixture of diastereomers which 
could be separated by flash column chromatography into a meso compound and a racemate. 
Intriguingly, both isolated products showed similar 1H and 13C NMR; but for all the bisalkylations, 
including the one in the bislysine synthesis, the minor isomer easily crystallized on standing at 
room temperature in the elution solvent (15% EtOAC in hexanes). The major product in all cases 
was isolated as an oil which foamed up under vacuum. For bislysine synthesis, both the compounds 
were carried forward and transformed into corresponding phthalimides. The deprotected 
phthalimide derivatives were then analyzed by HPLC where the racemate and meso isomers were 
identified. The major product was found to be the racemic mixture. For enzyme kinetics the (R,R) 
isomer was separated by semi-preparative HPLC at the phthalimide stage to obtain pure (R,R)-
bislysine. Primary enzyme inhibition studies with racemic and meso-bislysine showed that even 
though the desired stereoisomer is (R,R)- bislysine, it was possible to carry out preliminary 
experiments using the racemate. For all the reactions, monoalkylated products were also isolated 
and unreacted starting material was recovered back.  
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The synthesis of 23 (Scheme 3.6)  was achieved by using (2E)-1,4-dibromo-2-butene as 
the electrophile and following the exact route of bislysine synthesis. The alkylation proceeded in 
a similarly low yield, but nucleophilic displacement with phthalimide was more efficient (71% vs. 
50%). Hydrolysis of all protecting groups gave the desired compound after ion exchange 
chromatography.  
The synthesis of 26 is shown in (Scheme 3.7). 4-Nitrobenzyl bromide was used for the 
bisalkylation of 10, although this reaction proceeded with extremely low yield (1.5%) and the 
product was difficult to isolate because of the associated impurities. The product, in its impure 
form was subjected to hydrogenation to form 25, which could be isolated by column 
chromatography. The last step involved removal of tert-butoxycarbonyl protecting group and 
hydrolysis of methyl esters by refluxing in 5 M HCl to obtain 26 in very low overall yield.  
Synthesis of the triazole analogue 31 was attempted using the synthetic route of the simple 
lysine analog 20 described above, however, the procedure needed to be modified as shown in 
Figure 3.10. Propargyl bromide was used as the electrophile for bisalkylation, which proceeded in 
32% yield. Copper-catalyzed cycloaddition between benzyl azide and the acetylene 27 was 
performed at room temperature to obtain 28, however the debenzylation followed by acidic 
hydrolysis led to the decomposition of reaction mixture. Therefore, hydrolysis of the methyl ester 
groups was first performed using lithium hydroxide under mild conditions, followed by 
hydrogenolysis using H2 and palladium hydroxide as catalyst and lastly, the tert-butoxycarbonyl 
groups were removed using trifluoroacetic acid to obtain 31. All three of these steps proceeded in 
moderate to good yield (72 – 89%). The final compound was purified using ion-exchange column 
and eluted in 4M HCl. The resulting product was thus isolated starting from 10 in 10% yield over 
four steps. This compares with the yields over three steps from 10 of 17% for 23, ~ 0.2% for 26, 
and the previously reported 5% for bislysine. 
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Scheme 3.6  
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Scheme 3.7 
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Scheme 3.8 
3.4 Enzyme Inhibition Studies 
3.4.1 The DHDPS-DHDPR coupled assay 
A coupled assay refers to a method of measurement of enzymatic activity in which the 
enzyme under study is coupled with a second enzymatic reaction, which utilizes the product of the 
first reaction as its substrate. When the second enzyme is used in sufficient concentration, the first 
enzymatic reaction becomes the rate determining step. The DHDPS-DHDPR coupled assay was 
first described by Yugari and Gilvarg29 in 1965, where DHDPR was used to as the second enzyme 
(Figure 3.3). DHDPR is a NADH-dependent enzyme in the lysine biosynthesis pathway which 
reduces dihydrodipicolinate, the product of DHDPS-catalyzed reaction to tetrahydrodipicolinate. 
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During the course of the second reaction, NADH is oxidized to NAD+ which results in a decrease 
in the absorbance which can be monitored using a spectrophotometer. NADH absorbs strongly at 
340 nm (e = 6.22 M-1cm-1) while neither NAD+ or the product has absorbance in this range. In the 
presence of an excess of DHDPR, the decrease in the absorbance of NADH becomes the measure 
of the DHDPS-catalyzed reaction. For all the enzymatic studies described in this thesis, the 
coupled assay was used, the details of which are described in Section 5.2. 
 
 
Figure 3.3. The DHDPS-DHDPR coupled assay 
3.4.2 Measurement of enzyme activity 
The kinetic parameters of DHDPS were obtained using the coupled assay with respect to 
both the substrates, ASA and pyruvate. This was done to ensure that the new batch of the enzyme 
was active and kinetic parameters were comparable to those obtained previously in our lab. The 
experiment was performed by varying the concentration of one substrate at different fixed 
concentrations of the other substrate. The obtained kinetic data was fitted to ping pong rate 
equation using Sigmaplot 12.0® and kinetic parameters were obtained, 
v = VmaxAB / (KM(B)A + KM(A)B + AB) ....................................................3.1  
where v is the initial velocity, Vmax is the maximum velocity and KM(A) and KM(B) are the Michaelis-
Menten constants for the substrates A and B. As shown in Table 3.7. Kinetic parameters of DHDPS 
catalyzed reaction, DHDPS showed behavior similar to that previously reported.48 The double 
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reciprocal plots of Figure 3.4 A and B show parallel lines, which is diagnostic of a ping pong 
kinetic mechanism.70 This is consistent with the established reaction as described in Figure 1.11. 
 
Table 3.7. Kinetic parameters of DHDPS catalyzed reaction 
 Observed Reported48 
KM(ASA) 0.16 ± 0.01 mM 0.12 ± 0.01 mM 
KM(pyruvate) 0.35 ± 0.02 mM 0.27 ± 0.01 mM 
kcat 84 ± 1 s -1 76 ± 1 s -1 
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(A) 
 
 
(B) 
 
Figure 3.4. Double Reciprocal plot of the DHDPS-catalyzed reaction. Solid lines represent 
global fit of the data to Equation 3.1. (A) Concentration of pyruvate is varied (●) 0.15 mM 
(○) 0.30 mM (■) 0.50 mM (□) 1.5 mM (♦) 2.0 mM (◊) 3.0 mM. (B) Concentration of ASA is 
varied -(●) 0.13 mM, (○) 0.23 mM (■) 0.36 mM  (□) 0.90 mM (♦) 1.81 mM (◊) 3.39 mM.  
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3.4.3 Screening of inhibitors 
For enzyme inhibition studies, the DHDPS-DHDPR coupled assay was used with a fixed 
concentration of ASA (0.14 mM) and pyruvate (3 mM). The near-saturating concentration of 
pyruvate was chosen because it has been previously established by Skovpen and Palmer48 that 
allosteric inhibitor binding is enhanced by the presence of pyruvate. The near-KM concentration of 
ASA was chosen as a standard for comparison of each inhibitor. The inhibitor concentrations were 
selected in such a way that maximum number of data points could be recorded with the amount of 
inhibitor available. DHDPS activity was measured by recording the decrease in absorbance of 
NADH at 340 nm. The percent activity vs. inhibitor concentration plots were used to estimate the 
IC50, which is the concentration of inhibitor which causes 50% inhibition of the enzyme activity. 
IC50 values of compounds are indicative of their effectiveness as enzyme inhibitors. Since the assay 
is performed only with fixed concentrations of the substrate, the plot of relative activity vs. 
inhibitor concentration can be used as convenient way to evaluate the strength of the inhibitor. For 
example, the IC50 of (R,R)-bislysine was found to be ~ 0.3 μM. The steady state kinetic 
experiments revealed the Ki value to be 0.2 μM, which is similar in magnitude to the IC50 value. 
Synthesized inhibitors were tested using the DHDPS-DHDPR coupled assay described 
above, and the results are shown in Figure 3.4 and 3.5. It has previously been shown that the lysine 
L-thialysine (S-aminoethyl L-cysteine) is an allosteric inhibitor of DHDPS from C. jejuni, with an 
IC50 of be 2.2 mM.49 The 10-fold decrease in efficacy was very drastic since the only difference in 
thialysine structure is the presence of sulfur instead of carbon. However, it has been demonstrated 
that the pKa of thialysine is lower than that of lysine.71 Therefore, it was speculated that the pKa of 
the ε-amino group affects the activity of inhibitors. Apart from thialysine, α-methyl-D,L-lysine was 
shown to be a very poor allosteric inhibitor49, indicating that the allosteric site is very specific in 
terms of accommodating a compound. The analogues described in sections 3.3.1 and 3.3.2 were 
tested for inhibition against DHDPS and the percent activity curves were plotted to determine their 
potency.  
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Figure 3.5. Dimeric allosteric inhibitors of DHDPS and their IC50 values 
 
 
Figure 3.6. Monomeric allosteric inhibitors of DHDPS. 
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3.4.4 Amino acids as weak allosteric inhibitors 
 
Figure 3.7. (A) Amino acids showing no inhibitory effect on DHDPS and (B) weak allosteric 
inhibitors of DHDPS at pH 8. 
Naturally occurring amino acids histidine and arginine, which possess amino groups in their side 
chains, were tested for inhibition. Arginine showed a maximum of 55% inhibition at 14 mM 
concentration. Increase in inhibitor concentration did not inhibit the enzyme any further. The weak 
inhibition was as expected and it can be attributed to the structurally dissimilar side chain of 
arginine compared to lysine, with pKa 12.5. Because of these factors, even the presence of a 
hydrogen-bond donor did not make arginine a good inhibitor.  
 Histidine did not inhibit the enzyme activity. The imidazolylmethyl side chain is shorter 
than the aminobutyl group of lysine and perhaps places the terminal N-H of the imidazole ring 
further away from His59, making it difficult to form a hydrogen bond between the two groups. 
However, 2-amino-3-(1H-1,2,3-triazol-4-yl) propanoic acid 20, which is structurally similar to 
histidine, did show weak inhibition, with IC50 = 22 mM. The difference in these compounds is 
again, the pKa, which is near 7 for an imidazole side chain of histidine and near 9.5 for 20, closer 
to the pKa of lysine. This suggests that a pKa near 10 may be an important feature of any inhibitor.  
To further examine the importance of pKa, 4-amino-L-phenylalanine (4ALP) was tested for 
inhibition. The amino group at the para-position of the phenyl ring might be close to His59 when 
bound to the allosteric site, but the pKa is much lower (close to 5). It was expected that this 
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compound could behave as a weak inhibitor but even at 25 mM concentration there was no 
inhibition observed. The inhibition curves for weak inhibitors are shown in Figure 3.8. 
 
 
Figure 3.8. Inhibition of DHDPS by (±) lysine (♦), L-thialysine (■), (20) (○) and arginine (●). 
3.4.5 Enzyme inhibition by (±)-2,5-diamino-2,5-bis[(2E)-4-aminobut-2-en-1-yl] hexanedioic 
acid tetrahydrochloride (23) and (±)-(4E)-2,6-diaminohex-4-enoic acid (16) 
 
 
Figure 3.9. Moderate inhibitors of DHDPS at pH 8. 
The simplest modification introduced in the bislysine scaffold was addition of a double 
bond at carbon-4 of the side chain (Figure 3.9). The double bond provides more rigidity to the side 
chain by restricting bond rotation but the structure still has the 4-carbon side chain like lysine. It 
was observed that introduction of this double bond into lysine and bislysine raises the IC50 value 
4-fold for 23 (Figure 3.11) and 20-fold for 16 (Figure 3.12). This decrease in inhibitory activity 
may also be explained by a change in the pKa of the ε-amino group, which is lowered by the 
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presence of the double bond. It is well known that pKa values of allylic amines are about 1 unit 
lower than similar alkyl amines, as shown in Figure 3.10.72  
 
 
Figure 3.10. Comparison of pKa of aliphatic amines 
 
 
Figure 3.11. Inhibition of DHDPS by (±)-bislysine (●) and (23) (○). 
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Figure 3.12. Inhibition of DHDPS by (±)-lysine (♦) and (16)(◊) 
3.4.6 Enzyme inhibition using (±)-2,5-diamino-2,5-bis[(1H-1,2,3-triazol-4-yl)methyl] 
hexanedioic acid tetrahydrochloride (31) and 2,5-diamino-2,5-bis[(4-
aminophenyl)methyl] hexanedioic acid tetrahydrochloride (26). 
 
Figure 3.13. Bislysine analogues as weak inhibitors of DHDPS at pH 8. 
Although there were many difficulties faced while synthesizing the bis-para-
aminophenylalanine analog 26, it was important to test it as an inhibitor to see if the pKa effect 
was similar to that observed with 16 and 23. The introduction of an aromatic ring in a compound 
comes with advantages, such as more rigidity in the structure and increased molecular interactions. 
In the case of DHDPS it was important to explore the space available in the allosteric cavity and 
see if a large moiety can be accommodated as a part of the side chain. Both the analogues were 
assayed for inhibition. Interestingly, 26 showed 50% inhibition at 1 mM concentration which 
proved that the bulky aromatic ring did not prevent inhibitory activity (Figure 3.14). The higher 
IC50 value compared to other analogues can be a result of a drastic change in pKa of the side chain 
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amino group, or poor fit of the substrate in the allosteric site. The result with 26 was very 
encouraging for introducing aromatic rings in the side chains of inhibitor. Due to the poor yield of 
this synthesis, the activity curve could not be completed to get an estimate of the residual activity.  
 
(A) 
 
(B) 
 
 
Figure 3.14. Inhibition of DHDPS by (26) and (31). 
 
The dimeric analogs bislysine and 23 were more than 200-fold better inhibitors than the 
corresponding monomers. Therefore, it was expected that bis-triazolyl derivative 31 would have 
an IC50 value in micromolar range. The synthesis of 31 was comparatively easier than that of 26 
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and bislysine. The first alkylation step with propargyl bromide as well as the click reaction worked 
in moderate yield and large scale synthesis for further studies such as crystallization, binding 
experiments and cell based assays would be possible. The final compound also has only four 
charged groups at pH 8, which make it less polar and possibly more cell-permeable. Therefore, 
even high micromolar-range inhibition would have been an encouraging result. But surprisingly, 
31 showed only 20% inhibition below 5 mM, with an estimated IC50 of 12 mM (Figure 3.14). The 
available quantity of inhibitor only allowed measurements up to 12.5 mM concentration, which 
showed 62% inhibition. Even though 31 is better than its amino acid analogue, it is better by only 
2 fold, unlike other bislysine analogues. This result suggests that it is very important that the 
inhibitor can hydrogen bond with His59, and the length of the side chain of 31 may not allow that. 
Whether the pKa of the donor group is equally important needs to be examined further. Arginine 
and 23 are good examples of compounds with varying pKa but these compounds also have altered 
chain lengths which might be responsible for the lowered inhibition.  
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4 CONCLUSIONS  
 Significant improvement was not achieved in the bisalkylation of the protected 
diaminoadipate, suggesting that a different synthetic approach may be necessary to make 
this synthesis efficient. 
 Lysine analogues (α-amino acids) were synthesized in much higher yield compared to the 
bislysine analogues and all of them were poorer inhibitors than the bislysine analogues. 
The results obtained from lysine analogues can be used to estimate the activity of their 
dimeric counterparts, although the relationship between their activities is not linear. The 
lysine analogues thus offer an advantage because of the ease in their synthesis. 
 The bislysine analogue 23 is a weaker inhibitor than bislysine, despite being a close 
structural analog. The trans double bond of the side chain of 23 would allow it to adapt a 
similar configuration with fewer degrees of freedom (Figure 4.1). This supports the 
hypothesis that the pKa of the side chain -amino group is an important determinant of 
inhibition. 
 
Figure 4.1. The overlay of crystal structure of R,R-bislysine and its analogue 23. Bislysine is 
shown as green sticks and compound 23 in in black. 
 Lysine analog 20 is a weaker inhibitor than lysine, despite having a predicted pKa value 
closer to lysine. Both 26, with an aniline substituent and 31, with a triazole substituent were 
found to be less effective than bislysine. A possible explanation is that the inhibitors, which 
had their terminal amino groups farther away from His59, failed to make a strong hydrogen 
bond. The weak inhibition observed with these compounds could mean that they still bind 
in the allosteric site; but the binding is not as tight as other inhibitors This supports the 
hypothesis that the side chain hydrogen bonding interaction with His59 is sensitive to chain 
length. 
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Overall, this work highlights some important structural features of allosteric inhibitors 
which affect their activity. This knowledge can help to develop new class of antibacterial agents 
targeting the cell wall synthesis. The results obtained by this study can be used to synthesize more 
drug-like and potent inhibitors of DHDPS and extend the knowledge towards DHDPS from other 
bacterial species.  
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5 EXPERIMENTAL PROCEDURES 
5.1 Protein overexpression and purification 
Making cell stock: LB media (5 mL) containing 50 µg/mL ampicillin was inoculated from 
a single colony of E. coli XL1Blue transformed with recombinant plasmid pQE80L containing the 
C. jejuni dapA gene48. The cells were grown overnight at 310 K by shaking at 250 rpm. The cell 
suspension was then pelleted in 1.5 mL Eppendorf tubes by centrifugation. The cell pellets were 
suspended in a fresh media containing 0.5 mL LB broth with ampicillin (50 µg/mL) and 0.7 mL 
of 80% glycerol. These cell stocks were stored in –80 °C. 
Overexpression of protein: LB broth (500 mL) containing 50 µg/mL ampicillin was 
inoculated with 1 mL of cell stock and incubated at 310 K in a shaker at 250 rpm until it reached 
an optical density of 0.45. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final 
concentration of 0.5 mM to induce overexpression of protein. The incubation was continued for 
another 15 h at 288 K, before centrifugation at 5,180 × g for 30 min. The resulting cell pellet was 
suspended in 10 mL binding buffer (20 mM Tris –HCl, 5 mM imidazole, 500 mM NaCl, 12.5% 
glycerol, pH 7.9), chilled in an ice bath, and sonicated using a Virsonic 600 Ultrasonic Cell 
Disrupter. The resulting crude lysate was centrifuged at 27,000 × g for 30 min at 4 °C to separate 
the cell debris from the protein. The supernatant containing DHDPS was filtered through a 0.45 
μM syringe filter and loaded onto a 1-mL HiTrapTM  IMAC FF column (GE Healthcare), prepared 
according to the manufacturer’s procedure and equilibrated with 5 mL binding buffer, which 
facilitates the binding of the His-tagged protein to the column. The column was then washed with 
5 mL binding buffer, 5 mL 1:1 mixture of wash buffer (20 mM Tris –HCl, 100 mM EDTA, 500 
mM NaCl, 12.5% glycerol, pH 7.9) and binding buffer, 15 mL 1:1 mixture of strip buffer (20 mM 
Tris –HCl, 5 mM imidazole, 500 mM NaCl, 12.5% glycerol, pH 7.9) and binding buffer and then 
15 mL stripping buffer which results in the elution of the protein. Fractions were analyzed by SDS-
PAGE and the purest fractions were pooled and dialyzed at 4 °C for 24 h against 1 L storage buffer 
(20 mM Tris –HCl, 100 mM NaCl, 40% glycerol, pH 7.9). The resulting protein was concentrated 
to 0.59 mg/mL using an Amicon Ultra-15 Centrifugal Filter (30 kDa MWCO, EMD Millipore). 
Enzyme concentrations were determined by Nanodrop ND-1000 using calculated parameters 
(ProtParam) for DHDPS (MW 34069 Da, ε280 = 18068 M-1 cm-1).73 
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5.2 Enzyme assay 
The activity of DHDPS was measured using a coupled assay in which dihydropicolinate reductase 
(DHDPR) is present in sufficient quantity to oxidize NADH at a rate equal to the DHDPS catalyzed 
reaction.29 The ping pong kinetics experiments were performed to compare the kinetic parameters 
of DHDPS with the reported values in order to ensure that the enzyme was active. The second 
substrate of the enzymatic reaction, ASA was synthesized according to the reported procedure.74 
The kinetic measurements were performed on Beckman DU640 spectrophotometer at 25 ºC. A 
typical assay contained 100 mM HEPES buffer, 0.16 mM NADH, 0.45 μg DHDPS, 9.03 μg 
DHDPR and varying concentrations of ASA (0.13-3.39 mM) and pyruvate (0.15-3.00 mM). The 
initial velocity of DHDPS was determined using the decrease in absorbance of NADH (ε340 = 6220 
M-1cm-1) due to its oxidation. The experiment was performed by varying the concentration of one 
substrate at different fixed concentrations of the other substrate. For all the experiments, the 
reaction was initiated by the addition of the enzyme DHDPS. 
5.3 Organic synthesis of inhibitors 
All moisture- and air-sensitive reactions were performed under an inert atmosphere of nitrogen. 
The syringes, needles, magnetic stirring bars and glassware (flasks etc.) were dried at 120 °C 
overnight and cooled in desiccators. All chemicals were purchased from Sigma-Aldrich Canada, 
Ltd (Oakville, ON) or Alfa Aesar (Ward Hill, MA) unless stated otherwise.  Dry DCM and THF 
were obtained using a MB- solvent purification system (University of Saskatchewan). 
Diisopropylamine was freshly distilled from CaH2. Flash chromatography was performed using 
Merck silica gel 60 (230-400 mesh). Thin layer chromatography (TLC) was performed on 
precoated glass plates (Merck, silica gel 60, F 254) or aluminum plates. The spots were detected 
using UV light (254 nm) and by charring after treatment with cerium phosphomolybdate. Proton 
magnetic resonance (1H NMR) and carbon magnetic resonance (13C NMR) spectra were recorded 
on the Bruker 500 MHz spectrometer. Multiplicity is indicated by: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet) and br (broad). Mass spectra were recorded on a Q-star XL 
MS/MS System. Electron impact (EI) ionization was accomplished at 70 eV and chemical 
ionization (CI) at 50 eV. 
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(±)-Diethyl 2-[(2E)-4-bromobut-2-en-1-yl)]-2-acetamidopropanedioate 
  
The reaction was carried out according to the procedure described by Roduit and Wyler.66 
To a stirring solution of DEAM (4.00 g, 18.4 mmol) in dichloromethane (60 mL), 
tetrabutylammonium bisulfate (6.25 g, 18.4 mmol) was added in one portion followed by (2E)-
1,4-dibromo-2-butene (5.91 g, 27.6 mmol). A 20% aqueous sodium hydroxide solution (7.36 g, 
184 mmol) was then added dropwise over a period of 10 min. The resulting biphasic reaction 
mixture was stirred vigorously at room temperature. After 1 hour, the aqueous and organic layers 
were separated and the organic layer was concentrated by rotary evaporation. The resulting oil was 
partitioned between water (50 mL) and diethyl ether (50 mL). The layers were separated and the 
aqueous layer was washed with diethyl ether (2 × 20 mL). The combined Et2O layer was washed 
with brine and then evaporated under reduced pressure to get crude product which was purified by 
flash column chromatography (25% EtOAc in hexanes) to afford the product as white solid. (2.72 
g, 42%). m.p. 72-74 °C. 1H NMR (500 MHz, CDCl3) δ 6.73 (s, 1H), 5.76 (dt J = 15.2, 7.6 Hz, 
2H), 5.53 (dt J = 15.2, 7.6 Hz, 2H), 4.25 (qd J = 7.2, 1.1 Hz, 4H), 3.87 (d, J = 7.5 Hz, 2H), 3.09 
(d, J = 7.5 Hz. 2H), 2.03 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H). Spectral data matched the literature data. 
 
(±)-Diethyl 2-acetamido-2-[(2E)-4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)but-2-en-1-
yl]- propanedioate 
 
To a solution of 14 (2.72 g, 7.77 mmol) in dry DMF (15 mL), potassium phthalimide (4.31 
g, 23.3 mmol) was added in one portion. The resulting mixture was vigorously stirred for 16 h at 
90 °C. The reaction mixture was cooled to room temperature and DMF was removed under 
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reduced pressure. The residue was suspended in water (50 mL) and extracted with EtOAc (3 × 20 
mL). The combined organic layers were washed with water, brine and dried over Na2SO4. The 
solvent was removed under reduced pressure to yield crude product which was purified by flash 
column chromatography (50% EtOAc in hexanes) to obtain the pure compound as white solid 
(1.52 g, 47% yield). m.p. 130-132 °C. 1H NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 5.4, 3Hz, 4H), 
7.70 (dd, J = 5.4, 3Hz, 4H), 6.72 (s, 2H), 5.59-5.44 (m, 2H), 3.02 (d, J = 6.7 Hz, 2H), 4.19 (q, J = 
7.1 Hz. 6H), 1.98 (s, 3H), 1.20 (t, J = 7.1 Hz). 13C NMR (125 MHz, CDCl3) δ 169.1, 167.8, 167.5, 
134.1, 132.1, 128.7, 127.7, 123.3, 66.1, 62.6, 39.3, 35.4, 23.0. HRMS m/z calcd [M+Na]+ calcd 
C21H24N2O7Na 439.1481  observed 439.1472. 
 
 (±)-(4E)-2,6-diaminohex-4-enoic acid 
 
Aqueous HCl (5 M, 10 mL) was added to solid compound 15 (1.5 g, 3.60 mmol). The 
resulting mixture was stirred and refluxed for 24 h. The reaction mixture was cooled to room 
temperature and evaporated under reduced pressure to yield crude solid product which was purified 
by ion exchange chromatography using Dowex AG 50W X2 (acidic form). The crude was loaded 
on the column as an aqueous solution.  The column was washed with water (5 mL) followed by 
elution with 3 mL each of 1, 2, 3, and 4M HCl solution. The compound was eluted in 2M HCl and 
obtained as a pale yellow solid after evaporation. (0.69 g, 89%). 1H NMR (500 MHz, D2O) δ 5.91-
5.82 (m, 2H), 4.17 (t, J = 6.5 Hz, 1H), 2.83-2.71 (m, 2H), 5.91-5.82 (m, 2H). 13C NMR (125 MHz, 
CDCl3) δ 171.4, 129.7, 127.2, 52.3, 40.6, 32.6. HRMS m/z calcd for C6H13N2O2 [M+H]+ calcd 
145.0972, observed 145.0977.  
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(±)-Diethyl 2-acetamido-2-(prop-2-yn-1-yl) propanedioate 
 
The reaction was carried out using the procedure described previously,67,75 with some 
modifications. To a stirring solution of DEAM (500 mg, 2.30 mmol) in dry acetonitrile (20 mL), 
cesium carbonate (1.50 g, 4.60 mmol) was added in one portion. The resulting slurry was stirred 
at room temperature for 30 min. Propargyl bromide (80% solution in toluene, 0.51 mL, 3.4 mmol) 
was then added and the mixture was stirred at 50 °C for 16 h. The reaction mixture was cooled and 
the acetonitrile was evaporated under reduced pressure. The residue was suspended in water, and 
extracted with ethyl acetate (3 × 20 mL). The combined organic layer was washed with water, 
brine and then dried over Na2SO4. Solvent was removed under vacuum to obtain the crude which 
was purified by FCC (40% EtOAc in hexanes). The pure product was obtained as white solid 
compound (0.52 g, 88%). m.p. 92-94 °C. 1H NMR (500 MHz, CDCl3) δ 6.94 (s, 1H), 4.27-4.20 
(m, 4H), 3.24 (d, J = 2.5Hz, 2H), 2.04 (s, 3H), 1.95 (t, J = 3 Hz, 1H), 1.23 (t, J = 7.1 Hz, 6H). 13C 
NMR (125 MHz, CDCl3) δ169.3, 166.7, 78.3, 71.4, 65.3, 63.02, 23.8, 22.9, 14.0. 
 
(±)-Diethyl -2-acetamido-2-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]- propanedioate  
 
 To a solution of 17 (0.52 g, 2.0 mmol) in EtOH (5.0 mL), a 2.5 M aqueous solution of 
CuSO4 (0.046 mL, 0.115 mmol), followed by sodium ascorbate (0.23 g, 1.1 mmol) solution (2.5 
mL) was added so that the ethanol:water ratio was 2:1. Benzyl azide (0.52 mL, 4.1 mmol) was 
then added and the resulting biphasic reaction mixture was stirred vigorously for 24 h. EtOH was 
then removed under reduced pressure. The residue was diluted with water and extracted with ethyl 
acetate (3 × 20 mL). The organic extracts were combined, washed with brine and dried over 
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Na2SO4. Solvent was removed by rotary evaporation to give a crude oily product which was 
purified by FCC (60% EtOAc in hexanes) to obtain pure compound as white solid. (0.44 g, 56%). 
m.p. 74-76 °C.  1H NMR (500 MHz, CDCl3) δ 7.37-7.30 (m, 3H), 7.22-7.16 (m, 3H), 6.69 (s, 1H), 
5.45 (2H, s) 4.23 (q, J = 7.1 Hz, 4H), 3.72 (s, 2H), 1.90 (s, 3H), 1.22 (t, J = 7 Hz, 6H).13C NMR 
(125 MHz, CDCl3) 169.2, 167.4, 142.4, 134.8, 129.2, 128.8, 128.0, 122.9, 66.1, 62.9, 54.1, 29.1, 
23.0, 14.0. HRMS m/z calcd for C19H25N4O5 [M+H]
+ calcd 389.1780, observed 389.1810. 
 
1,3-Diethyl 2-acetamido-2-(1H-1,2,3-triazol-4-ylmethyl) propanedioate 
 
To a solution of 18 (440 mg, 1.13 mmol) in ethyl acetate (2.0 mL) in a hydrogenation flask, 
10% Pd/C (44 mg, 10% by wt. of 18) was added followed by methanol (5.0 mL). After two 
vacuum/H2 cycles to replace air inside the flask with H2, the reaction mixture was vigorously 
stirred at room temperature under 60 psi for 24 h. The reaction mixture was then filtered through 
a bed of Celite®. The filtrate was collected and solvent was removed under reduced pressure to 
obtain 23 as colorless solid, (0.31 g, 92 %). 1H NMR (500 MHz, MeOD) δ 7.54 (s, 1H), 4.23 (m, 
4H), 3.72 (s, 2H), 2.02 (s, 3H), 1.24 (t, J = 7.1 Hz, 6H). 13C NMR (125 MHz, MeOD) δ 172.8, 
168.3, 67.8, 63.70, 29.6, 22.30, 14.3. HRMS m/z calcd for C12H18N4O5 [M+H]
+ calcd 289.1277, 
observed 299.1362. 
 
2-amino-3-(1H-1,2,3-triazol-4-yl) propanoic acid 
 
Aqueous HCl (5 M, 5 mL) was added to solid compound 19 (80 mg, 0.27 mmol). The 
resulting mixture was stirred and refluxed for 24 h. The reaction mixture was cooled to room 
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temperature and evaporated under reduced pressure to yield crude solid product which was purified 
by ion exchange chromatography using Dowex AG 50W X2 (acidic form). The crude was loaded 
on the column as an aqueous solution.  The column was washed with water (5 mL) followed by 
elution with 2 mL each of 1, 2, 3, and 4M HCl solution. The compound was eluted in 2M HCl and 
obtained as a pale yellow solid after evaporation. (45 mg, 89%). 1H NMR (500 MHz, D2O) δ 7.91 
(s, 1H), 4.30 (t, J = 6 Hz, 1H), 3.35 (dd, J = 6, 2.5 Hz, 2H).13C NMR (125 MHz, D2O) δ 170.5, 
138.8, 127.0, 52.2, 24.9. HRMS m/z calcd for C5H9N4O2 [M+H]
+ calcd 157.0720, observed 
157.0718.  
 
Dimethyl 2,5-dibromohexanedioate 
 
Compound 6 was obtained using the procedure reported by Skovpen and Palmer.59  Neat 
thionyl chloride was added to adipic acid (20.0 g, 137 mmol) and refluxed under an inert 
atmosphere at 80 °C for 3 h. Excess thionyl chloride (25 mL, 342 mmol) was removed under 
reduced pressure to obtain adipoyl chloride (25.0 g, 137 mmol) as a colorless oil. For bromination, 
the reaction set up consisted of a 2-neck 1 L round bottom flask equipped with a reflux condenser 
and a dropping funnel. The assembly was placed in an oil bath on an electronic stirrer and charged 
with adipoyl chloride.  Effluent from the condenser was vented into a beaker with 250 mL 10% 
sodium thiosulphate solution to trap the bromine gas. Additionally, a 500W lamp was placed close 
to the reaction flask. The lamp was turned on and the assembly was heated to 80 °C. To the adipoyl 
chloride, neat bromine (17.6 mL, 342 mmol) was added using the dropping funnel very slowly, 
over a period of 3 hours. The bromination reaction was monitored by NMR and additional bromine 
was added if required. After the reaction was complete (7-8 h) the excess bromine was removed 
by purging with a stream of nitrogen into the flask, and the crude product was added dropwise to 
cold methanol (140 mL) on ice. The resulting suspension was left stirring for 14 h at room 
temperature. The product was then filtered. The filtrate was concentrated under reduced pressure 
and purified by FCC (15% ethyl acetate in hexanes) to give more product. Yield 43.03 g 46%. 1H 
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NMR (500 MHz, CDCl3) δ 4.24 (s, 1H), 3.78 (s, 3H), 2.34-1.95 (m, 2H). Spectral data matched 
with the literature data. 
 
Dimethyl 2,5-bis(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)hexanedioate 
 
 
The mixture of stereoisomers of 7 was obtained using a reported method.58 To a stirring 
solution of 6 (43.03 g, 129.6 mmol), in dry DMF (150 mL), potassium phthalimide (120 g, 648 
mmol) was added in one portion. The mixture was heated to 90 °C and the reaction continued for 
2h. The cooled reaction mixture was then diluted with chloroform and the resulting solution was 
poured into water. The chloroform layers were combined, and the solvent was removed in vacuo 
to the point of crystallization followed by addition of diethyl ether to promote rapid crystallization. 
The solid product was filtered, washed with diethyl ether and dried to obtain white solid. FCC 
(30% ethyl acetate in hexanes) afforded the title compound as white solid, (45g, 53%). 1H NMR 
(500 MHz, CDCl3) δ 7.91-7.85 (m, 4H), 7.89-7.74 (m, 4H), 4.81(t, J = 5.0 Hz, 2H), 3.66 (s, 6H), 
2.39-2.29 (m, 2H), 2.29-2.19 (m, 2H). Spectral data matched with the literature data. 
 
2,5-Diaminohexanedioic acid 
 
The reaction was performed according to the procedure reported by Skovpen and Palmer.59 
To the mixture of stereoisomers of 7 (20.0 g, 43.1 mmol), a 1:1 mixture (100 mL) of 48% aqueous 
HBr and glacial acetic acid was added and the mixture was refluxed at 115 °C while stirring. The 
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hydrolysis was complete after 25 days. (The reaction mixture becomes clear). The reaction mixture 
was cooled and filtered to remove phthalic acid and filtrate was evaporated in vacuo. The residue 
was dissolved in water, filtered and neutralized with saturated ammonium hydroxide solution. The 
resulting white precipitate was filtered and dried. The product was isolated as a mixture of 
stereoisomers (7.66 g, 89% yield). 1H NMR (500 MHz, CD3OD) δ 4.06 (d, J = 2.2Hz, 2H), 2.30-
2.00 (m, 4H). Spectral data matched with the literature data.  
 
Dimethyl 2,5-diaminohexanedioate dihydrochloride 
  
The reaction was performed according to the procedure reported by Skovpen and Palmer.59 
A round bottom flask was charged with methanol (120 mL) and cooled on ice under nitrogen. 
Acetyl chloride (15.4 mL, 216 mmol) was added dropwise over a period of 10 min. The solid 
compound 8 (6.35 g, 36.0 mmol) was added rapidly and the resulting suspension was heated to 
reflux. After 2 h, the mixture was cooled and the solvent was evaporated in vacuo to obtain a white 
crystalline product as the dihydrochloride salt (9.89 g, 99%) The product was used without further 
purification. 1H NMR (500 MHz, CD3OD) δ 4.18-4.15 (m, 2H), 3.87 s, 6H, 2.23-1.96 (m, 4H). 
Spectral data matched the literature data.  
 
Dimethyl 2,5 bis([(tertbutoxy)carbonyl]amino)hexanedioate 
 
The protection of the amino groups was carried out using the reported procedure by 
Skovpen and Palmer.59 To a suspension of 9 (4.82 g, 17.4 mmol) in THF (50 mL) placed an in ice 
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bath, trimethylamine (7.33 mL, 52.2 mmol), was added dropwise under N2 atmosphere. A solution 
of di-tert-butyl dicarbonate (11.4 g, 52.2 mmol) in THF (20 mL) was then added to the reaction 
mixture over a period of 1 h. The reaction was warmed to room temperature and stirred for 16 h 
after which the temperature was raised to 50 ºC and maintained for 3 hours. The reaction mixture 
was then allowed to cool and the solvent was removed under reduced pressure. The resulting 
suspension was partitioned between ethyl acetate (30 mL) and saturated sodium bicarbonate (60 
mL) solution. The organic layer collected and the extraction was repeated twice with ethyl acetate 
(30 mL). The combined organic layers dried over sodium sulfate and concentrated in vacuo. The 
resulting sticky residue was stirred in diethyl ether (50 mL) for 1 h in ice-water bath to induce 
crystallization. The white solid obtained was filtered under vacuum and dried. The filtrate was 
collected and after concentrating in vacuo, was subjected to flash column chromatography (30% 
ethyl acetate in hexanes) to obtain the remaining compound. The total yield was 5.31g, 75%. 1H 
NMR (500 MHz, CDCl3) δ 5.08 (br s, 2H), 4.30 (br m, 2H), 3.73 (s, 6H), 1.92-1.82 (m, 2H), 1.73-
1.65 (m, 2H), 1.44 (s, 18H). Spectral data matched the literature data. 
 
 (±)-Dimethyl 2,5 bis([(tertbutoxy)carbonyl]amino)-2,5-bis[(2E)-4-bromobut-2-en-1-yl]- 
hexanedioate 
 
To a dry round bottom flask charged with THF (20 mL), freshly distilled diisopropylamine 
(1.50 mL, 10.7 mmol) was added under nitrogen atmosphere. The solution was cooled to –78 °C 
and n-butyllithium, 2.35 M solution in hexanes (4.3 mL, 10.0 mmol) was added dropwise. The 
reaction was warmed to 0 °C and stirred at the same temperature for 20 min. The reaction mixture 
was again cooled to –78 °C and a solution of 10 (0.900 g, 2.22 mmol) in THF (5 mL) was added 
dropwise over a period of 15 min under nitrogen atmosphere and stirred at the same temperature 
for 1 h. A solution of (2E)-1,4-dibromo-2-butene (2.37 g, 11.1 mmol) in THF was then added 
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dropwise to the reaction and it was stirred for 2 h maintaining the temperature at –78 °C. The 
cooling was then removed and the reaction was quenched by adding saturated ammonium chloride 
solution (20 mL). The aqueous layer was extracted with ethyl acetate (4 × 20 mL). The combined 
organic layers were washed with water, then brine and dried over solid Na2SO4. The solvent was 
then removed under reduced pressure to get crude product which was purified by FCC (15% ethyl 
acetate in hexane) and two diastereomers 21A (22 mg, 1.5% yield) and 21B (0.15 g, 9.3% yield) 
were isolated as white crystalline solid (21A) and sticky solid (21B). Compound 21B was obtained 
as a crystalline solid after standing in hexanes for 3 days. It was carried forward for the next step 
and later confirmed as a racemic mixture by HPLC. The formation of racemic mixture as the major 
product was in agreement with the previously reported reaction in the synthesis of bislysine.59 (A) 
m.p. 125-126 °C. 1H NMR (500 MHz, CDCl3) 5.59-5.48 (m, 3H), 5.70 (dt, J = 15, 7.5 Hz, 2H), 
3.91-3.83 (m, 4H), 3.75 (s, 6H), 3.13-2.99 (m, 2H), 2.43 (dd, J = 13.6, 7.4 Hz, 2H), 1.70 (d, J = 
8.75 Hz, 2H), 1.44 (s, 18H). 13C NMR (125 MHz, CDCl3) δ 173.1, 153.6, 130.6, 129.5, 63.3, 52.9, 
38.1, 32.4, 30.0, 28.3. (B) m.p. 132-134 °C.  1H NMR (500 MHz, CDCl3) δ 5.73 (dt, J = 15, 7.5 
Hz, 2H), 5.54 (dt, J = 15, 7.5 Hz, 2H), 5.39 (br s, 2H), 3.87 (d, J = 5 Hz, 4H) 3.75 (s, 6H), 2.94 (br 
s, 2H), 2.51 (dd, J = 10, 5 Hz, 2H), 2.21 (s, 2H), 1.55-1.50 (m, 2H), 1.43 (s, 18H). 13C NMR (125 
MHz, CDCl3) δ 173.3, 154.0, 130.9, 129.4, 79.6, 62.86, 52.8, 38.0, 32.4, 29.6, 28.4. HRMS m/z 
calcd for C26H42Br2N2O8Na [M+Na]
+ 693.1185 observed 693.1144 
 
 (±)-Dimethyl ({[(tert-butoxy)carbonyl]amino})-2,5-bis[(2E)-4-(1,3-dioxo-2,3-dihydro-1H-
isoindol-2-yl)but-2-en-1-yl]hexanedioate  
 
 
To a solution of racemic 21B (0.060 g, 0.074 mmol) in dry DMF (5 mL), solid potassium 
phthalimide (0.033 g 0.22 mmol) was added in one portion at room temperature. The reaction 
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mixture was heated to 100 °C and stirred for 3 h. It was then cooled to room temperature and DMF 
was evaporated under reduced pressure. The residue was suspended in water (10 mL) and extracted 
with ethyl acetate (5 mL × 3). The combined organic layers were washed with water, then brine, 
and then dried over Na2SO4. The solvent was then removed under vacuum to yield crude product 
which was purified by FCC (60% ethyl acetate in hexanes) to get a colorless sticky solid (0.042 
mg, 70% yield). 1H NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 5.5, 3Hz, 4H), 7.69 (dd J = 5.5, 3Hz, 
4H), 5.58- 5.46 (m, 4H), 5.31 (br s, 2H), 2.50-2.39 (m, 2H), 2.13 (br s, 2H), 1.54-1.44 (m, 2H), 
1.35 (m, 18H) 13C NMR (125 MHz, CDCl3) δ 173.5, 168.0, 154.1, 134.1, 132.3, 128.9, 128.1, 
123.4, 79.5, 62.8, 52.8, 39.6, 38.1, 29.9, 28.4. HRMS m/z calcd for C42H51N4O12 [M+H]
+ 803.3497, 
found 803.3503. 
 
(±)-2,5-Diamino-2,5-bis[(2E)-4-aminobut-2-en-1-yl]hexanedioic acid tetrahydrochloride 
 
To compound 22 (0.030 g, 0.037 mmol) in a round bottom flask, 5M HCl (2 mL) was 
added and the resulting mixture was stirred and refluxed for 24 h. The reaction mixture was cooled 
to room temperature and evaporated to dryness under reduced pressure to yield a brownish residue 
which was purified by ion exchange chromatography using Dowex AG 50W X2. The product was 
eluted in 4 M HCl and obtained as a colorless solid after evaporation of the fractions (6 mg, 35% 
yield). 1H NMR (500 MHz, D2O) δ 5.90- 5.80 (m, 4H), 3.63 (d, J = 5.0 Hz, 4H), 2.81 (dd, J = 14, 
6 Hz, 2H), 2.67 (dd, J = 14, 6 Hz, 2H), 2.13-2.04 (m, 2H), 2.02-1.92 (m, 2H). 13C NMR (500 MHz, 
D2O) δ 172.8, 128.8, 128.4, 63.1, 40.64, 38.0, 29.6. HRMS m/z calcd for C14H26N4O4 [M+H]+  
315.1988, found 315.2026. 
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Dimethyl 2,5-bis({[(tert-butoxy)carbonyl]amino})-2,5-bis[(4-nitrophenyl)methyl] 
hexanedioate 
 
To a dry round bottom flask charged with THF (10 mL), freshly distilled diisopropylamine 
(0.41 mL, 2.97 mmol) was added under nitrogen atmosphere. The solution was cooled to –78 °C 
and a freshly titrated n-butyllithium solution in hexanes (1.18 mL, 2.78 mmol) was added dropwise 
over a period of 10 min. The reaction was warmed to 0 °C and stirred at the same temperature for 
20 min. The reaction mixture was again cooled to –78 °C and a solution of 10 (0.25 g, 0.62 mmol) 
in THF (3 mL) was added dropwise over a period of 10 min under nitrogen atmosphere. A solution 
of 4-nitrobenzyl bromide in THF was then added dropwise to the reaction and it was stirred for 2 
hours maintaining the temperature at –78 °C. The cooling was then removed and the reaction was 
quenched by adding saturated NH4Cl solution (10 mL) and extracted with ethyl acetate (10 mL × 
3). The combined organic layers were washed with water, brine and dried over solid Na2SO4. The 
solvent was then removed under reduced pressure to get crude product which was purified by FCC 
(15% EtOAc in hexanes) twice to obtain product with ~70% purity as estimated by NMR (25 mg, 
1.5%). This product was carried forward without further characterization. 
 
Dimethyl 2,5-bis[(4-nitrophenyl)methyl]-2,5-bis({[(tert-butoxy)carbonyl]amino}) hexanedioate 
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To a solution of 24 (0.025 g, 0.037 mmol) in ethyl acetate (2 mL) in a hydrogenation flask, 
10% Pd/C (0.003 g, 10% by wt. of 24) was added followed by methanol (2 mL). After two 
vacuum/H2 cycles to replace air inside the flask with H2, the reaction mixture was vigorously 
stirred at room temperature under 60 psi for 3 h. The reaction mixture was then filtered through a 
bed of Celite®. The filtrate was collected and solvent was removed under reduced pressure to 
obtain 25 as sticky yellowish solid (5 mg, 32%).1H NMR (500 MHz, MeOD) δ 6.78 (d, J = 8 Hz, 
4H), 6.56 (d, J = 8.5 Hz, 4H), 5.42 (s, 2H), 3.77 (s, 6H), 3.59 (br s, 3H), 3.46 (d, J = 14.1 Hz, 2H), 
2.91 (d, J = 13.8 Hz, 2H), 2.74 (s, 1H), 2.12-2.16 (m, 2H), 1.87-1.80 (m, 2H), 1.48 (s, 18H). 13C 
NMR (125 MHz, MeOD) δ 173.43, 153.83, 145.13, 130.5, 129.4, 126.5, 79.0, 65.1, 40.4, 37.6, 
30.5, 28.6. HRMS m/z calcd for C32H46N4O8Na [M+Na]
+  615.3349, found 615.3391. 
 
2,5-diamino-2,5-bis[(4-aminophenyl)methyl] hexanedioic acid tetrahydrochloride 
 
To compound 25 (0.005 mg, 0.008 mmol) in a round bottom flask, 5M HCl (2 mL) was 
added and the resulting mixture was stirred and refluxed for 24 h. The reaction mixture was cooled 
to room temperature and evaporated to dryness under reduced pressure to yield crude solid product 
which was purified by ion exchange chromatography using Dowex AG 50W X2 (acid form). The 
column was eluted with one mL each of 1, 2, 3, 4 and 5M HCl solution. Each fraction (0.50 mL) 
was evaporated to dryness to record 1H NMR. The product was detected in 4 M HCl. The fractions 
containing the product were combined and evaporated to dryness to obtain a colorless solid. (2.7 
mg, 63% yield). 1H NMR (500 MHz, D2O) δ 7.34 (s, 8H), 3.81(d, J = 3.05, 1H), 3.41 (d, 2H, J = 
14.5 Hz), 3.11(d, J = 14.5 Hz, 2H), 2.31(m, 2H), 1.88-1.83(m, 2H).13C NMR (125 MHz, D2O) δ 
173.2, 134.2, 131.64, 129.6, 123.5, 64.8, 41.4, 30.3. HRMS m/z calcd for C20H27N4O4 [M+H]
+  
387.1998, found 387.2024. 
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(±)-Dimethyl ({[(tert-butoxy)carbonyl]amino})-2,5-bis[(prop-2-yn-1-yl]hexanedioate  
 
 
To a dry round bottom flask charged with THF (15 mL), freshly distilled diisopropylamine 
(1.00 mL, 7.12 mmol) was added under nitrogen atmosphere. The solution was cooled to –78 °C 
and n-butyllithium, 2.25 M solution in hexanes (2.96 mL, 6.673 mmol) was added dropwise. The 
reaction was warmed to 0 °C and stirred at the same temperature for 20 min. The reaction mixture 
was again cooled to –78 °C and a solution of 10 (0.600 g, 1.48 mmol) in THF (4 mL) was added 
dropwise over a period of 10 min under nitrogen atmosphere and stirred at the same temperature 
for 45 min. Propargyl bromide solution (5.9 mmol, 0.88 mL, 80% in toluene) was then added 
dropwise to the reaction and it was stirred for 2 hours maintaining the temperature at –78 °C. The 
cooling was then removed and the reaction was quenched by adding saturated NH4Cl solution (15 
mL). THF was then removed under vacuum and the aqueous layer was extracted thrice with ethyl 
acetate (15 mL × 4). The combined organic layers were washed with water, then brine, and dried 
over solid Na2SO4. The solvent was then removed under reduced pressure to obtain crude product 
which was purified by FCC (15% EtOAc in hexanes). Two diastereomers were isolated as white 
solids 27A, (67 mg, 9%). m.p. 171-173 °C and 27B (0.161 g, 23%). m.p. 139-140 °C. 1H NMR 
(500 MHz, CDCl3) δ 5.60 (br s, 2H), 3.76 (s, 6H), 3.16 (d, J = 16.3 Hz, 2H), 2.69 (d, 16.8 Hz, 2H), 
2.12-2.01 (m, 2H), 1.95 (s, 2H), 1.74 (d, J = 9.1 Hz, 2H), 1.49 (s, 18H). (B). 1H NMR (500 MHz, 
CDCl3) δ 5.49 (s, 2H), 3.76 (s, 6H), 3.03 (br d, J = 15.5 Hz, 2H), 2.82 (d, J = 17 Hz), 2.18 (br s, 
2H), 1.96 (s, 2H), 1.63-1.55 (m, 2H), 1.43 (s, 18H). 13C NMR (125 MHz, CDCl3) δ 172.5, 154.2, 
80.0, 79.2, 71.1, 61.7, 53.1, 29.1, 28.4, 25.9. HRMS m/z calcd for C24H37N2O8 [M+H]
+ 481.2544, 
observed 481.2553. 
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(±)-Dimethyl ({[(tert-butoxy)carbonyl]amino})-2,5-bis[(1benzyl-1H-1,2,3-triazol-4-
yl)methyl]hexanedioate  
 
 
To a solution of 27B (0.140 g, 0.291 mmol) in EtOH (5 mL), a 0.25 M aqueous solution of 
CuSO4 (0.058 mL, 0.014 mmol) followed by sodium ascorbate (0.29 g, 0.14 mmol) solution (2.5 
mL) was added. Neat benzyl azide (0.12 mL, 0.87 mmol) was then added and the resulting biphasic 
reaction mixture was stirred vigorously for 36 h at room temperature. EtOH was then removed 
under reduced pressure. The residue was diluted with water and extracted with ethyl acetate (3 × 
20 mL). The organic extracts were combined, washed with brine, and dried over Na2SO4. Solvent 
was removed to get crude oily product which was purified by FCC (60% EtOAc in hexanes) to 
obtain pure compound as a colorless solid (0.13 g, 62%). m.p. 150-151°C. 1H NMR (500 MHz, 
CDCl3) 7.39-7.30 (m, 6H), 7.25-7.20 (m, 4H), 7.13 (s, 2H), 5.49-5.40 (m, 6H), 3.75 (s, 6H), 3.55 
(d, J = 15 Hz, 2H), 3.24 (d, J = 15 Hz, 2H), 2.30-2.19 (m, 2H), 1.30 (s, 18H).13C NMR (125 MHz, 
CDCl3) δ 173.0, 153.8, 143.0, 134.6, 129.0, 128.6, 128.0, 122.6, 79.2, 62.6, 53.9, 52.8, 31.3, 30.1, 
28.2. HRMS m/z calcd for C38H50N8O8Na [M+ Na]
+ 769.3649, observed 769.3643. 
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(±)-({[(tert-Butoxy)carbonyl]amino})-2,5-bis[(1benzyl-1H-1,2,3-triazol-4-
yl)methyl]hexanedioic acid  
 
To a solution of 28 (0.125 g, 0.167 mmol), in methanol (5 mL), solid LiOH·H2O (0.028 g, 
0.67 mmol) was added in one portion at room temperature. The reaction was warmed to 40 °C and 
stirred for 4 h, after which methanol was removed under vacuum. The residue was diluted with 
water, acidified with 5% citric acid solution and extracted with EtOAc (10 mL × 3). The organic 
extracts were combined, washed with brine and dried over Na2SO4. Solvent was removed to get 
crude oily product which was purified by FCC (4% MeOH/DCM) to obtain pure compound as 
colorless solid (0.13 g, 62%). The resulting white solid was used for the next step without further 
purification (0.092 g, 0.128 mmol, 72%). 1H NMR (500 MHz, CDCl3) δ 7.37-7.28 (m, 6H), 7.23-
7.12 (m, 6H), 5.66 (br s, 1H), 5.49-5.37 (m, 4H), 3.74 (br s, 1H), 3.68-3.56 (m, 2H), 3.79-3.25 (m, 
2H), 2.49- 2.26 (m, 2H), 1.80 (t, J = 12 Hz, 1H), 1.36-1.17 (m, 18H) HRMS m/z calcd for 
C36H45N8O8 [M-1]
- 717.3366, observed 717.3439. 
 
 
 (±)-({[(tert-Butoxy)carbonyl]amino})-2,5-bis[(1H-1,2,3-triazol-4-yl)methyl]hexanedioic acid  
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To a solution of 29 (0.090 g, 0.12 mmol) in ethyl acetate (2.0 mL) in a hydrogenation flask, 
10 % Pd(OH)2 0.009 g, 10% by wt. of 29) was added followed by methanol (5.0 mL). After two 
vacuum/H2 cycles to replace air inside the flask with H2, the reaction mixture was vigorously 
stirred at room temperature under 60 psi for 8 hours. The reaction mixture was then filtered through 
a bed of Celite®. The filtrate was collected and solvent was removed under reduced pressure to 
obtain pale white amorphous solid (0.060 g, 89%).The compound was used for the next step 
without further purification. 1H NMR (500 MHz, MeOD) δ 7.47 (s, 2H), 3.49 (d, J = 14.9 Hz, 
2H), 3.39 (d, J =14.9 Hz, 2H), 2.19-2.07 (m, 2H), 1.44 (s, 18H). HRMS m/z calcd for C22H33N8O8 
[M-1]- 537.2426 observed 537.2427 
 
(±)-2,5-Diamino-2,5-bis[(1H-1,2,3-triazol-4-yl)methyl] hexanedioic acid tetrahydrochloride 
 
 
A mixture of compound 30 (0.060 g, 0.11 mmol) in DCM (2.0 mL) was cooled to 0 ᵒC. 
Trifluoroacetic acid (2.0 mL) was then added dropwise and the resulting solution was warmed to 
room temperature. After 15 min, the reaction mixture was evaporated to dryness under reduced 
pressure to yield crude solid product which was purified by ion exchange chromatography using 
Dowex AG 50W X2 and eluting in 4 M HCl. The fractions containing the product were evaporated 
to dryness to get a colorless solid (0.027 g, 77% yield). 1H NMR (500 MHz, D2O) δ 7.81 (d, J = 
12 Hz, 1H), 3.75 (s, 1H), 3.48-3.43 (m, 2H), 3.35-3.30 (m, 2H), 2.18-1.95 (m, 4H). 13C NMR (125 
MHz, D2O) δ 171.3, 169.9, 138.1, 127.4, 62.5, 62.3, 54.1, 30.3, 29.1.  HRMS m/z calcd for 
C12H17N8O4 [M-1]
- 337.1378, observed 336.1363. 
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